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Abstract 
African swine fever (ASF) is a lethal hemorrhagic disease of swine caused by a double-
stranded DNA virus. ASFV is endemic in Sardinia and Saharan Africa and has been 
recently expanded from the Caucasus to Eastern Europe. There is no vaccine to 
prevent the disease and current control measures are limited to culling and restricted 
animal movement. Swine infected with attenuated strains are protected against 
challenge with a homologous virulent virus, but there is limited knowledge of the host 
immune mechanisms generating that protection. Swine infected with Pret4 virus 
develop a fatal severe disease, while a derivative strain lacking virulence-associated 
gene 9GL (Pret4Δ9GL virus) is completely attenuated. Swine infected with Pret4 Δ9GL 
virus and challenged with the virulent parental virus at 7, 10, 14, 21, and 28 dpi showed 
a progressive acquisition of protection (from 40% at 7 dpi to 80% at 21 and 28 dpi). This 
animal model was used to associate the presence of host immune response and 
protection against the challenge. The presence of anti-ASFV antibodies, as well as 
ASFV-specific IFN-γ production in PBMCs, and cytokines in serum were assessed in 
each group. Interestingly, with the exception of ASFV-specific antibodies in the surviving 
swine challenged at 21 and 28 dpi, no solid association between any of the parameters 
assessed and the extent of protection could be established. These results were 
corroborated using a similar model based on the use of a rationally attenuated 
derivative of the highly virulent strain Georgia 2007. These results, encompassing data 
from over 114 immunized swine, underscore the complexity of the system under study 
where it is very plausible that protection against disease or infection relies heavily on 
the concurrence and or interaction of different host immune mechanisms.  
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Abstract 
African swine fever (ASF) is a lethal hemorrhagic disease of swine caused by a 
double-stranded DNA virus. ASFV is endemic in Sardinia and Saharan Africa and has 
been recently expanded from the Caucasus to Eastern Europe. There is no vaccine to 
prevent the disease and current control measures are limited to culling and restricted 
animal movement. Swine infected with attenuated strains are protected against 
challenge with a homologous virulent virus, but there is limited knowledge of the host 
immune mechanisms generating that protection. Swine infected with Pret4 virus 
develop a fatal disease, while a derivative strain lacking the virulence-associated gene 
9GL (Pret4Δ9GL virus) is completely attenuated. Swine infected with Pret4 Δ9GL virus 
and challenged with the virulent parental virus at 7, 10, 14, 21, and 28 dpi showed a 
progressive acquisition of protection (from 40% at 7 dpi to 80% at 21 and 28 dpi). This 
animal model was used to associate the presence of host immune response and 
protection against challenge. Anti-ASFV antibodies and cytokines in serum, as well as 
ASFV-specific IFN-γ production in PBMCs, were assessed in each group. Interestingly, 
with the exception of ASFV-specific antibodies in the surviving swine challenged at 21 
and 28 dpi, no solid association between any of the parameters assessed and the 
extent of protection could be established. These results were corroborated using a 
similar model based on a rationally attenuated derivative of the highly virulent strain 
Georgia 2007. These results, encompassing data from 114 immunized swine, 
underscore the complexity of the system under study where it is very plausible that 
protection against disease or infection relies heavily on the concurrence and or 
interaction of different host immune mechanisms.
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Chapter 1 - Introduction to African swine fever virus 
 1.1 African swine fever 
 1.1.1 African swine fever virus 
African swine fever (ASF) is a highly contagious hemorrhagic disease of 
domestic swine, feral swine, and wild boar (Sus scrofa) first described in 1921 in Kenya 
by Montgomery (Eustace Montgomery, 1921). This disease is transmitted directly 
between infected swine by the oro-nasal route, indirectly by ingestion of contaminated 
food or through feeding by infected tick vectors. Aerosol transmission occurs only over 
very short distances. Unlike domestic swine, infections of other susceptible members of 
the Suidae family, including the warthog (Phacochoerus aethiopicus), giant forest hog 
(Hylochoerus meinertzhageni), Red River hogs (Potamochoerus porcus), and Bushpigs 
(Potamochoerus larvatus) are generally asymptomatic with low viremia (Anderson et al., 
1998; Luther et al., 2007; Oura et al., 1998; Sanchez-Vizcaino et al., 2012). It is thought 
that these asymptomatic carriers are reservoir hosts for the virus in Africa, but further 
investigation is necessary since several species of suids have different roles in the 
epidemiology of ASF depending on taxonomy, geography, and the extent of contact 
between domestic swine and wildlife (Jori and Bastos, 2009). Although the literature 
describes a specific relationship between soft ticks and wild suids including warthogs 
and bushpigs in East and Southern Africa (Plowright, 1981; Thomson, 1985), this does 
not apply to all of Africa. For instance, in West African nations a feral swine 
epidemiology of ASF has not been established and the existence of a sylvatic cycle 
involving the connection between soft ticks and warthogs is still in question (Jori et al., 
2013). ASFV can be maintained in a sylvatic cycle between Suidae species and argasid 
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ticks including Ornithodoros moubata and erraticus, but two additional virus cycles are 
also recognized in Africa’s endemic areas including a pig-tick cycle where warthogs are 
not a part of the cycle and another where ASFV persists in domestic swine without any 
sylvatic host, invertebrate or vertebrate (Jori and Bastos, 2009; Penrith and Vosloo, 
2009). Young warthogs become infected when bitten by infected ticks and develop a 
transient viremia for a few weeks that is sufficient to infect more ticks (Thomson, 1985; 
Thomson et al., 1980). Both wild boar and feral swine are highly susceptible to ASFV 
and develop clinical disease with mortality rates similar to domestic swine (Denis, 
2014). The exact role of bushpigs still eludes us, although there are reports 
demonstrating them as free-living hosts infected with ASF experimentally and under 
natural conditions (Denis, 2014; Luther et al., 2007; Oura et al., 1998). The giant forest 
hog in Africa has also demonstrated active infection but its role in ASF spread still 
remains to be understood (Penrith and Vosloo, 2009).  
Following the spread of ASF into Portugal in 1957 as a result of waste from 
airline flights being fed to pigs near Lisbon, the disease was not eradicated from the 
Iberian Peninsula until the mid 1990’s (Costard et al., 2009). The tick vector was 
implicated as a long-term reservoir host, as the disease reappeared on a Portuguese 
farm where infected ticks were discovered in 1999 (Costard et al., 2009). Adult ticks and 
large nymphs can survive for up to 5 years in the presence of swine to feed on (Oleaga-
Perez et al., 1990). These factors alone make the control and eradication of ASF 
extremely difficult. 
ASF is a severe disease with drastic socio-economic consequences, and it is 
notifiable to the World Organization for Animal Health (OIE). There are no vaccines 
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available and the only methods of control are surveillance, epidemiological 
investigations, strict quarantine and biosecurity measures, control of animal movement, 
and finally slaughter of all infected animals (Beltrán-Alcrudo et al., 2009). These control 
measures significantly impact the national and international trade of pigs and pig 
products.  
 1.1.2 Classification 
The etiologic agent of ASF is African swine fever virus, an enveloped double-
stranded DNA virus of the genus Asfivirus within the Asfarviridae family. This virus 
shares features of Poxviridae, Iridovividae, Phycodnaviridae, and Mimiviridae (Tulman 
et al., 2009). It is the only arthropod-borne (arbo) virus with a double-stranded DNA 
genome. 
 1.1.3 Morphology and structure 
ASFV particles have a complex multi-layered structure (Carrascosa et al., 1984). 
The virion is approximately 200 nm in diameter (Breese and DeBoer, 1966) and 
contains more than 50 polypeptides. The virion core is about 80 nm in diameter and it is 
comprised of an electron-dense nucleoprotein enclosed by a matrix or core shell 
(Andres et al., 2002; Andres et al., 1997). The core contains the virus genome, 
enzymes, and other proteins necessary for the early stages of infection after viral entry 
(Dixon et al., 2008). The core or thick protein layer is surrounded by two lipid bilayers, 
called the inner membrane. The icosahedral capsid is just external to this inner 
membrane and is composed of the structural protein p72 encoded by B646L (Salas and 
Andres, 2013). The capsid is formed by 1892 to 2172 hexagonal capsomeres (Andres 
et al., 2001; Breese and DeBoer, 1966; Carrascosa et al., 1984). This makes up about 
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one third of the protein content of the virion (Tulman et al., 2009). ASFV capsomeres 
are in a hexagonal lattice arrangement individually consisting of 13 nm hexagonal 
arrangements with a central hole (Carrascosa et al., 1984). The outside of the capsid is 
a loose external membrane obtained by virion budding through the plasma membrane, 
which is not necessary for virus infection. Two-dimensional analysis of Percoll gradient 
purification of extracellular ASFV revealed 54 structural proteins with molecular weights 
from 10,000 to 150,000 Daltons (Esteves et al., 1986).  
 
 
Figure 1.1 Structure and assembly of extracellular ASFV particles  
Electron microscopy with epon sectioning (A), cryosectioning (B), and negative 
staining (C) (Andrés et al., 1998). Electron microscope methods show a central 
core surrounded by three layers: the inner envelope (ie), the capsid (c), and the 
outer envelope (oe). Small arrows in C are individual capsomeres. Bars: 50 nm. 
(Andrés et al., 1998). 
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Figure 1.2 Structure and protein composition of ASFV (Salas and Andres, 2013). 
 
 1.1.4 Genome 
The linear double-stranded DNA genome has 170-193 kbp in 151-167 open-
reading frames (ORFs) located on both strands (Blasco et al., 1989b; Dixon et al., 
2013b; Tabares et al., 1980; Tulman et al., 2009). The length of the genome varies due 
to the gain or loss of sequences from the 5’ and 3’ ends of the genome, which encode 
copies of six multigene families (MGF100, MGF110, MGF300, MGF360, MGF530, and 
P22) (Dixon et al., 2008). The organizational makeup of these gene families may shed 
light on viral evolution by gene duplication and antigenic variation. Multiple copies of 
multigene families may give the virus a selective advantage allowing immune evasion 
(Dixon et al., 2008). The large ASFV genome comprises several genes involved in 
nucleotide metabolism, transcription, DNA replication and repair, immune evasion, and 
the regulation of apoptosis (Dixon et al., 2013b). 
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The genomic locations of some of the structural proteins have been identified. 
P220 (CP2475L) and pp60 (CP530R) form part of the core shell. P54 (E183L) is an 
important membrane protein in the internal envelope. The external envelope of the virus 
particle contains CD2v, the hemadsorption protein encoded by ORF EP402R 
(Rodriguez et al., 1993). P72 (B646L) is a major virus capsid component that is used for 
genotyping. 
 Previously, twenty-two genotypes had been described based on the C-terminal 
end of the P72 gene (Bastos et al., 2003; Lubisi et al., 2005; Michaud et al., 2007). 
ASFV genotyping mainly involves genes that code for the viral proteins p54 (E183L), 
p72 (B646L) and the central variable region (CVR) within B602L. Isolates from eastern 
and southern Africa are more diverse and separate into 21 genotypes; Western Africa, 
Western Europe including Sardinia, and South America cluster in genotype I (Bastos et 
al., 2003; Boshoff et al., 2007; Lubisi et al., 2005). Genotype II mostly contains eastern 
European isolates (Gallardo et al., 2014). More recently, Achenbach (Achenbach et al., 
2016) analyzed ASFV from domestic swine from 2011 to 2014 identifying a new 
genotype 23, sharing ancestry with genotypes 9 and 10 commonly found in eastern 
Africa and the Republic of the Congo. Phylogenetic studies reveal relative strain 
homogeneity among isolates from all sources in Western Africa, Europe, and America, 
and strain heterogeneity with isolates from Southern and Eastern Africa. 
Malogolovkin (Malogolovkin et al., 2015) has proposed a serogrouping 
classification of worldwide strains based on the extracellular portion of the CD2v protein 
using hemadsorption inhibition (HAI). HAI typing places ASFV into discrete serogroups 
that are not related to P72 capsid protein genotypes. For example, ASFV of serogroups 
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1, 2 and 4 fall into P72 genotype 1 (Malogolovkin et al., 2015). The use of HAI is 
impractical for routine ASFV serogrouping since it requires live virus and convalescent 
serum from rarely surviving animals, because HAI antibodies appear late and at low 
titers during infection (Malmquist, 1963; Malogolovkin et al., 2015; Ruiz Gonzalvo et al., 
1986b; Ruiz-Gonzalvo and Coll, 1993; Vigario et al., 1974).  
 
Figure 1.3  Comparison of the Georgia 2007/1 ASFV genome with those of other 
ASFV isolates (Chapman et al., 2011).  
The ASFV phylogeny midpoint was rooted in a neighbor-joining tree on the basis 
of 125 conserved open reading frame regions (40,810 aa) from 12 viruses. Node 
values show percentage bootstrap support (n = 1,000). The isolates shown and 
accession numbers are Kenya AY261360, Malawi Lil20/1 AY261361, Tengani 
AY261364, Warmbaths AY261365, Pretoriuskop AY261363, Warthog AY261366, 
Warmbaths AY261365, Mkuzi AY261362, OurT88/3 a.m.712240, BA71V NC_001659, 
Benin97/1 a.m.712239, and E75 FN557520. Scale bar indicates nucleotide 
substitutions per site (Chapman et al., 2011). 
 
 
 8 
Figure 1.4 Organization of ASFV genomes (Dixon et al., 2013b). 
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The genomic organization of the Georgia 2007/1 isolate is shown in Fig 1.4 
(Dixon et al., 2013b). Black arrows indicate ORFs encoding enzymes involved in DNA 
replication, repair, or transcription. Grey represents ORFs for structural proteins. Pink 
indicates ORFs for evading host immune defenses. Multigene families are indicated by 
turquoise, blue, green, brown, and mauve. Yellow represents proteins with various other 
predicted functions, and white represents proteins of unknown function. Red represents 
ORFs whose deletion reduces virulence (Dixon et al., 2013b). 
 1.1.5 Virus replication 
ASFV infects monocytes in peripheral blood and macrophages found throughout 
the host. Infection has also been demonstrated in hepatocytes, endothelial cells, and 
renal tubular cells. The virus can also replicate in soft ticks of the genus Ornithodoros 
(Burrage, 2013; Casal et al., 1984; Coggins, 1974; Fernandez et al., 1992). Peripheral-
blood mononuclear cell (PBMC) cultures infected with ASF virus show cytopathic 
changes (cell rounding and margination of nuclear chromatin) leading to degeneration 
of cells at 2-3 days and finally cell detachment at 4-8 days (Gomez-Villamandos et al., 
2013; Moulton and Coggins, 1968b). ASFV DNA replication occurs at 5-10 hours post-
infection in cell culture (Tulman et al., 2009), and from 8-10 hours post-infection 
onwards these cultures generally show hemadsorption or forming of rosettes after the 
addition of swine erythrocytes. ASFV morphogenesis occurs at the perinuclear viral 
factories near the Golgi complex and microtubule organizer center, surrounded by 
endoplasmic reticulum cisternae and mitochondria (Salas and Andres, 2013). A number 
of studies investigating viral entry used tissue culture cells. DNA replication and virus 
morphogenesis occurs within the cytoplasm close to the cell nucleus. Earlier studies 
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demonstrated that extracellular ASFV enters macrophages by receptor-mediated 
endocytosis (Alcami et al., 1989, 1990). Receptor-mediated endocytosis, dynamin-
dependent and clathrin-mediated endocytic pathways were also identified as the 
principal ways for ASFV entry in Vero cells, wild boar lung cells (WSL), and 
macrophages (Galindo et al., 2015; Hernaez and Alonso, 2010). The presence of 
cholesterol in cellular membranes was found to be key in a successful ASFV infection. 
Phosphoinositide-3-kinase (PI3K) activity and actin-dependent endocytosis are also 
required (Galindo et al., 2015). Other studies stated that ASFV triggers its own uptake 
by macropinocytosis (Hernaez et al., 2016; Sanchez et al., 2012). 
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Figure 1.5 Diagram of ASFV internalization and uncoating, adapted from (Hernaez 
et al., 2016) 
In figure 1.5, ASFV is shown entering a macrophage by clathrin-mediated endocytosis 
and constitutive macropinocytosis. Once the virus is taken up by the cell, the particles 
are transported from early endosomes or macropinosomes to late endosomes. Next, 
these transported viruses undertake the un-coating process in low pH conditions 
necessary for capsid disassembly and disruption of the outer viral membrane. 
Afterwards, the inner viral envelope will fuse with the endosomal membrane where the 
genome within the naked core enters the cellular cytosol. Some of the disrupted 
particles may reach lysosomes, they may fuse or be degraded, as lysosomal hydrolases 
may contribute to virus disruption or un-coating (Hernaez et al., 2016). 
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Once the virus enters the cells, the outer membrane is lost. ASFV is internalized 
in endosomes and then a low pH induces fusion between the viral membrane and 
vesicle membrane, causing the release of virus cores into the cytoplasm. Early mRNA 
synthesis begins in the cytoplasm using enzymes and factors packaged in the virus 
core. ASFV transcription occurs independently of host RNA polymerase, as productive 
infection requires the cell nucleus. The mechanisms of ASFV replication and 
transcription are similar to poxviruses, with the exception of viral DNA in the nucleus. 
Early virus proteins encode enzymes necessary for DNA replication, and subgenomic 
fragments at early stages of DNA replication of are found in the cell nucleus. 
Microtubules are necessary in the formation of perinuclear factories. DNA replication in 
the factories is followed by a shift to gene transcription to late virus genes. These genes 
encode structural proteins, enzymes, and factors required for virus particles in the next 
round of infection. The virus assembly takes place in factories, then the mature virions 
move on microtubules to the plasma membrane. ASFV particles exit from infected cells 
once transported from the virus factories to the plasma membrane. Other theories 
suggest the virus release and spread with the observation of ASFV inducing apoptosis 
at late stages of infection. Viral particles in apoptotic bodies may provide a means to 
evade the immune system by avoiding exposure of extracellular virions to the host 
immune system. Interestingly it has been speculated that macrophages also recognize 
scavenger receptors and may take up apoptotic bodies with virus particles (Dixon et al., 
2008). 
In other studies, ASFV infection has been related to the maturation stage of the 
macrophage which is linked to the expression of the CD163 scavenger receptor 
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(Sanchez-Torres et al., 2003), however it has also been found that ASFV can replicate 
in cells that do not express CD163 (Dixon et al., 2013a; Lithgow et al., 2014). This 
highlights the importance of further investigation in understanding ASFV replication and 
cell receptor usage. 
 1.2 African Swine Fever History, Global Distribution 
 1.2.1 Epidemiology and global impact 
ASFV was first described in Kenya in 1910 (Eustace Montgomery, 1921) with the 
earliest outbreaks outside of Africa in Lisbon, Portugal, in 1957 (Blasco et al., 1989a; 
Manso Ribeiro et al., 1958; Vinuela, 1985). In 1959, a second outbreak occurred 
resulting in ASF spreading from the Iberian Peninsula to France, Italy, Malta, Belgium, 
and the Netherlands (Penrith et al., 2009). In the late 1970s, Brazil (1978), Cuba (1977), 
the Dominican Republic (1978), Haiti (1979), and other Caribbean islands also reported 
ASF outbreaks. ASF first spread to West Africa in Senegal in 1978 and Cameroon in 
1982, and recently information has emerged about the presence of ASF in Nigeria and 
Cape Verde in the 1960-70s (Penrith et al., 2009). ASF historically has been introduced 
to disease-free areas by feeding of domestic animals with contaminated pork products 
imported via airports or seaports. ASF then establishes itself in the domestic pig 
population from where it disseminates further. The distribution of ASF changed in the 
1990s and 2000s, as many countries including Côte d’Ivoire (1996), Nigeria (1997), 
Togo (1997), Ghana (1999), Burkina Faso (2003), Chad (2010), Madagascar (1998), 
Portugal (1999) and Mauritius (2007) reported outbreaks.  
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Figure 1.6 Map illustrating different ASFV outbreaks prior to the 2000’s, from 
ASForce.org. 
Several factors contributed to the spread of ASF to new territories, including 
globalization, the financial crisis forcing small farmers to feed swill or garbage to their 
animals, the high tenacity of ASFV in the environment and in meat products, as well as 
the occurrence of asymptomatic carrier animals. By the late 1990s many European 
countries had managed to eradicate ASF, with the exception of Italy (Sardinia). ASF is 
still endemic in Sardinia and affects domestic pigs, wild boar, and feral pigs. Carrier 
ticks are not found in Sardinia and are not involved in the transmission or persistence of 
ASF in this case. It is likely the free-range or backyard-farming systems that increase 
the risk of outbreaks (Mannelli et al., 1997; Sanchez-Vizcaino et al., 2015). 
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Figure 1.7 World Animal Health Information System (WAHIS) African swine fever 
distribution map January-June 2015 (OIE Accessed Feb 2016) 
In April 2007, the Caucasus region (Georgia) reported several ASF outbreaks 
and since then the virus has spread to Armenia, Azerbaijan, Russia, Ukraine, Belarus, 
Estonia, Latvia, Lithuania, and Poland. Genetic studies of ASFV isolates from Russia 
and the Caucasus region suggest that one strain arrived in 2007 and subsequently 
spread. These isolates closely resemble p72 genotype II found in Mozambique, 
Madagascar, and Zambia (Rowlands et al., 2008). It is thought that infected swill from 
international ships was fed to swine near the port of Poti on the eastern shore of the 
Black Sea, the site of first entry of ASF in the Caucasus region (Beltrán-Alcrudo et al., 
2009). 
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Figure 1.8 WAHIS African Swine Fever outbreak map April 2007-January 2016 
(OIE, accessed Feb 2016) 
 1.3 ASFV pathogenesis 
 1.3.1 Clinical signs and lesions 
The incubation period of ASF varies from 5 to 15 days with morbidity and 
mortality ultimately reaching 100%. Clinical disease is usually peracute or acute, but 
depending on the virulence of the virus strain, the clinical signs, duration, and course of 
an ASFV infection can vary from a highly acute clinical presentation with death in under 
10 days to a long-term persistent infection. Many animals suffer from severe 
thrombocytopenia and lymphopenia during this clinical course, but ASF may manifest 
as subacute or chronic when less virulent strains are involved (Penrith et al., 2009). 
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 1.3.1.1 Peracute presentation of ASF 
If swine are peracutely infected with ASFV, they are often found dead without 
prior clinical signs, but they can also be pyrexic, have rapid shallow breathing, can be 
recumbent or huddling together with other pigs, and fair-skinned pigs in particular may 
appear flushed. 
 1.3.1.2 Acute presentation of ASF 
Swine suffering from acute ASF develop a persistent fever up to 42°C (107.6°F). 
Clinical signs may last two to seven days. Animals appear flushed to cyanotic with 
erythema on the tips of the ears, and pinpoint to ecchymotic hemorrhages may be 
visible on the skin. They may be recumbent or listless, and anorexic. Mucopurulent 
ocular and nasal discharges may be apparent. They appear to be uncomfortable, arch 
their backs, or show ataxia or lameness in their limbs. Infected swine may present with 
vomiting and bloody diarrhea. Swine may also suffer from dyspnea and bloody froth 
from the mouth and nostrils indicative of lung edema. Some swine may also develop 
central nervous signs including convulsions. Abortions can occur at any stage and 
usually result from the high fever; vertical transmission does not occur (Penrith et al., 
2009). 
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Figure 1.9 Swine inoculated with Pretoria parental strain 5 days post-challenge 
(own photos)  
  
  
  
  
  
 
  
Figure 1.10 Swine inoculated with Pretoria parental strain, red tipped (erythema) 
ears 8 days post-challenge (own photo) 
1.3.1.3 Subacute presentation of ASF 
Subacute presentation of ASF with longer survival is seen in pigs when they are 
infected with a less virulent strain. These animals will have undulating fever and lose 
their body condition. Often interstitial pneumonia is observed and clinically presents as 
respiratory distress and moist coughing. Frequently secondary bacterial infections will 
ensue. Pigs can have swollen and painful joints. Pigs may die in weeks or months or 
they may recover and progress to a chronic form of the disease. Cardiac lesions may be 
present and result in acute or congestive heart failure (Penrith et al., 2009).  
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1.3.1.4 Chronic presentation of ASF 
Chronically infected swine lose body condition, may appear emaciated and their 
growth is stunted. Animals commonly have lameness and ulcers or pressure wounds 
over bony points. Often these pigs are prone to secondary bacterial infections and signs 
of pneumonia may also occur. These animals can survive for many months but a full 
recovery is unlikely (Penrith et al., 2009). 
1.3.1.5 Necropsy and lesions of ASF 
The most common post-mortem lesion is an enlarged, friable, dark red to black 
spleen. Lymph nodes are enlarged and hemorrhagic. Most commonly lesions are found 
in the tonsils, and the gastrohepatic, trachealbronchial, mediastinal, renal, and 
mesenteric lymph nodes. Kidneys often have petechial hemorrhages. The stomach may 
be deeply congested or hemorrhagic on the mucosal surface. Hemorrhages may also 
be observed on the gall bladder and urinary bladder. Focal skin necrosis, fibrinous 
pericarditis, pericardial effusion, multifocal epicardial hemorrhages, ascites, swollen 
joints, and lungs with consolidation and edema often occur. 
 
 
 
 
 
 
Figure 1.11 Swine inoculated with Pretoria parental strain: multifocal 
hemorrhages on skin (own photo)  
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Figure 1.9 Swine inoculated with Pretoria parental strain: pinpoint focal 
hemorrhages on kidney, and hemorrhagic renal lymph nodes (own photo) 
 
 
 
 
 
 
 
 
 
 
Figure 1.10 Swine inoculated with Pretoria parental strain, melena in intestines 
(own photo) 
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Figure 1.11 Swine inoculated with Pretoria parental strain: interlobular pulmonary 
edema and consolidation (own photos) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12 Swine inoculated with Pretoria parental strain swine, enlarged spleen 
(left), hemorrhagic tracheobronchial lymph node (right) (own photos) 
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Figure 1.13 Swine inoculated with Pretoria parental strain: pinpoint focal 
hemorrhages on kidney (left) and enlarged hemorrhagic retropharyngeal lymph 
node (right) (own photos) 
 
 1.3.1.6 Histopathological lesions of ASF 
ASF viral infection in tissues often results in massive destruction of macrophages 
and extensive apoptosis of lymphocytes and lymphopenia (Gomez-Villamandos et al., 
1995; Gonzalez-Juarrero et al., 1992; Sanchez-Cordon et al., 2008; Sanchez-Vizcaino 
et al., 1981). Karyorrhexis in the lymphoid tissues is often a remarkable feature. 
Fibrinoid changes are often found in blood vessel walls as a result of necrosis of the 
endothelium and leakage of inflammatory mediators. Interstitial pneumonia with fibrin 
and macrophage infiltrate is commonly found in the lungs. Within the kidneys, renal 
tubular degeneration with hyaline droplet absorption is observed. The portal tracts of the 
liver will be infiltrated with macrophages. In the brain, lymphocytic meningoencephalitis 
can be visible. 
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 1.4 Strategies for control 
 1.4.1 Disinfection of ASF 
Preventing the spread of ASFV is a critical aspect and most importantly should 
focus on regulating the import of pork products and ensuring proper disposal or 
decontamination of fomites on planes and ships. 
ASFV is stable in the environment over a wide range of temperatures and pH (2-
11). ASFV can be inactivated by sunlight and desiccation, but is relatively stable in 
excretions of infected swine, carcasses, meat products; putrefaction, freezing, or 
thawing does not inactivate the virus. ASFV can remain infective in feces for at least 11 
days and for months in bone marrow (Beltrán-Alcrudo et al., 2009). ASFV can survive in 
chilled meat for 15 weeks and 3-6 months in cured hams and sausages that have not 
been cooked or smoked at high temperatures (2010; Mebus et al., 1993; William A. 
Geering, 2001).  
Sodium hypochlorite bleach (10%), citric acid (2%) and some iodine and 
quaternary ammonium compounds have been reported as effective against ASFV on 
nonporous surfaces (Krug et al., 2012). Higher concentrations can be used to disinfect 
the virus on wood surfaces. 
There are recommendations that otherwise unprocessed meat must be heated to 
70°C for 30 minutes to inactivate ASFV. To inactivate virus in serum and body fluids 
heating to 60°C for 30 minutes is sufficient. Altering the pH to less than 3.9 or greater 
than 11.5 in serum-free medium also can inactivate the virus (Spickler, 2015). Since it is 
difficult to determine if all aspects of swill are cooked properly, most countries forbid its 
use. 
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 1.4.2 Laboratory diagnostics 
Rapid laboratory diagnosis is key to distinguishing ASF from other diseases such 
as classical swine fever, bacterial septicemia, porcine dermatitis and nephropathy 
syndrome, acute porcine reproductive and respiratory syndrome, erysipelas, Glaesser’s 
disease, pseudorabies, thrombocytopenic purpura, and other general septicemic or 
hemorrhagic conditions (Jean Gladon, 2011). 
ASF can be diagnosed via virus isolation on primary cultures of porcine 
macrophages (cultured from peripheral blood, bone marrow, or alveolar lavage) using 
samples from blood or tissues such as spleen, kidney, liver, tonsil, and lymph nodes. 
Virus isolation of ASFV is typically performed on primary culture of porcine 
macrophages isolated from the peripheral blood or lungs of swine. Primary leukocyte 
cultures may also be derived from bone marrow or lung lavages. ASFV-infected cells 
are detected by adding homologous swine erythrocytes. Once macrophages are 
actively infected, the erythrocytes form rosettes around infected cells, this is known as 
hemadsorption. Hemadsorption is a sensitive and specific method, but it is important to 
note that some isolates are non-hemadsorbing (Gonzague et al., 2001; Pini and 
Wagenaar, 1974). PCR or immunofluorescence are often used to detect the virus. The 
fluorescent antibody test (FAT) allows for fast detection of antigen on cryopreserved 
sections or impression smears obtained at necropsy.  
The viral genome may also be detected by polymerase chain reaction (PCR). 
PCR is particularly useful when samples are unsuitable for virus isolation. It should be 
noted that ASFV is not found in aborted fetuses, but blood from the sow should be 
sampled.  
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Serology may be useful where the disease is endemic, but often pigs die before 
developing antibodies against ASFV. However, animals that survive will have antibodies 
that will persist for long periods. Current serological assays include ELISA, 
immunoblotting, and indirect fluorescent antibody (IFA) test. 
 
 
 
 
 
 
 
 
 
 
Figure 1.14 Hemadsorption detection of ASFV-infected macrophages cultured 
from porcine peripheral blood (own photo) 
 1.4.3 Vaccine strategies 
Currently there are no vaccines or effective treatments available against ASF. 
The lack of heterologous protection among strains of ASFV represents an obstacle in 
our research. Vaccine development began in the 1960s when scientists first attenuated 
ASF virus by cell passage. These attenuated viruses (e.g. strain Lisbon60) were able to 
stimulate an antibody response and prevent acute death after challenge at 117 dpi. 
(Manso Ribeiro et al., 1963; Stone et al., 1968). There have been several failed 
attempts to vaccinate animals using infected cell extracts, supernatants of infected 
PBMCs, inactivated virions, glutaraldehyde-fixed infected macrophages, or detergent-
treated infected alveolar macrophages (Coggins, 1974; Forman et al., 1982; Kihm et al., 
1987; Mebus, 1988; Neilan et al., 2004). 
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It has been said that ASF was able to establish itself enzootically in Portugal and 
Spain after the use of an unsafe ASF vaccine in the 1960s and 1970s (Coggins, 1974; 
Dixon et al., 2013a; Hess, 1971; Manso Ribeiro et al., 1963). Europe observed more 
chronic and subclinical infections in domestic pigs in the 1960-1970s than East Africa 
(Coggins, 1974; Hess, 1971; Scott, 1965). A large number of carrier animals were 
generated, hindering subsequent attempts to eradicate ASF (Hess, 1971). Since the 
use of this vaccine caused adverse post-vaccination reactions including pneumonia, 
locomotor changes, skin ulcers, and even death, no further field trials of attenuated 
vaccines were carried out (Dixon et al., 2013a; Manso Ribeiro et al., 1963). 
Swine that survive primary ASFV infection or have been inoculated with 
attenuated ASFV often resist homologous challenge with the parental strain (Coggins, 
1974). Coggins also reported that vaccinated pigs frequently had transitory protection 
against the challenge virus, and often develop a chronic form of the disease with lesions 
in the lungs, pericardium, and skin over the bony prominences. Even pigs that did not 
respond clinically to ASFV may still have histopathologic lesions such as hyperplasia of 
reticular cells and lymph nodes, where virus was often isolated (Coggins et al., 1968; 
Moulton and Coggins, 1968a).  
Swine that survive ASFV infection against one genotype generally have solid 
immunity to challenge from a homologous strain but not against heterologous strains 
even if they are considered the same genotype (King et al., 2011; Leitao et al., 2001; 
Manso Ribeiro et al., 1963; Mulumba-Mfumu et al., 2015). Effective control of ASF will 
hinge on the availability of several vaccines based on specific isolates in found in each 
region. 
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 1.4.3.1 Inactive and subunit vaccines 
Experimental inactivated and subunit vaccines have been consistently 
unsuccessful in protecting swine from ASFV infection (Coggins, 1974; Forman et al., 
1982; Mebus, 1988). Kihm et al. demonstrated some level of protection (50%) of pigs 
against ASFV using an inactivated vaccine from spleen mixed with Freund’s adjuvant, 
however all pigs were found to be viremic between 4 and 18 days post-challenge. The 
virus persisted in spite of high antibody titers until at least 91 days post-inoculation and 
early antibody detection had no correlation with protection (Kihm et al., 1987). 
In 2004, Neilan et al. immunized swine with baculovirus-expressed p30, p54, 
p72, and p22 from Pretoria (Pret4) (Neilan et al., 2004). Although ASFV specific 
neutralizing antibodies were detected in vaccinates, swine exhibited only a two-day 
delay to the onset of clinical disease with reduced viremia at 2 DPI. However, naïve 
animals and vaccinates both died between 7 and 10 days post-infection. 
Lacasta et al. demonstrated that a DNA vaccine encoding p54, p30, and the 
hemagglutinin extracellular domain fused with ubiquitin provided partial protection in the 
absence of detectable antibodies prior to virulent challenge (Lacasta et al., 2014). In this 
case, only 50% of the vaccinated pigs survived the challenge, and 2 out of 8 swine 
showed no viremia or viral excretion post-infection. The subunit vaccines induced partial 
protection with 33-50% of immunized animals surviving challenge (Argilaguet et al., 
2012; Lacasta et al., 2014). 
More recently, Blome et al. conducted an experiment to re-assess binary 
ethyleneimine (BEI) inactivated ASFV preparations (strain Armenia 08) formulated with 
current adjuvants Polygen or Emulsigen-D. The modern adjuvants did not enhance the 
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efficacy of BEI-inactivated ASFV vaccines. Antibodies were detected in vaccinates, but 
no neutralization or protection was observed (Blome et al., 2014).  
Unfortunately, there is no vaccine available for ASFV despite many attempts with 
inactivated viruses or subunit vaccines. Previous attempts using attenuated vaccines 
demonstrated good potential in protecting swine against virulent homologous challenge.  
 1.4.3.2 Live attenuated viruses as vaccines 
Protective vaccination is feasible because complete protection can be achieved 
by infection with low-virulence isolates of ASFV. Convalescent swine develop strain-
specific immunity that can withstand challenge with antigenically related virulent strains. 
ASFV strains attenuated naturally, by cell culture passage, and targeted gene deletions 
have been used to create rationally attenuated strains that elicit protective immune 
responses (Abrams et al., 2013; Hamdy and Dardiri, 1984; Leitao et al., 2001; Lewis et 
al., 2000; Mebus and Dardiri, 1980; Neilan et al., 2004; O'Donnell et al., 2015a; 
O'Donnell et al., 2015b) 
In the past, the main issue with attenuated viral strains was biosafety. Some 
attenuated strains retained virulence and produced sub-clinical and possibly chronic 
infections in swine (Coggins et al., 1968; Sanchez Botija, 1963). Now with advances in 
molecular virology we can genetically attenuate ASFV in a more controlled manner. 
Pigs immunized with live attenuated ASFVs containing genetically engineered 
deletions of specific virulence-associated genes are protected when challenged with 
homologous parental viruses. Specifically, individual deletions of 23-NL (DP71L), UK 
(DP69R), TK (A240L, 9GL (B119L), or multiple genes from MGF 530/505 and MGF 360 
from the genomes of virulent ASFV viruses including Malawi Lil-20/1 (Mal), 
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Pretoriuskop/96/4 (Pret4), E70 and Georgia 2007 resulted in significant attenuation of 
these isolates in swine (Lewis et al., 2000; Moore et al., 1998; O'Donnell et al., 2015a; 
O'Donnell et al., 2015b; Zsak et al., 1998; Zsak et al., 1996). 
Previously it was described that NL-S with similarity to the neurovirulence-
associated gene (ICP34.5) in herpes simplex virus is not essential for viral replication in 
swine macrophages in culture (Zsak et al., 1996). Deletion of NL-S resulted in 
attenuation of the virus in domestic swine, signifying its relevance as a viral virulence 
factor (Zsak et al., 1996). Swine infected with ∆NL-S E70 remained clinically normal for 
30 days and with 1,000 fold reduction in mean and maximum viremia titers compared to 
virulent E70 (Zsak et al., 1996).  
Interestingly, it should be noted that the same deletion of NL-S in Pret4 and 
Malawi Lil 20/1 did not cause attenuation and mortality was 100% in domestic swine 
(Afonso et al., 1998). This data suggests that the E70 strain isolated in Spain in 1970, 
years after its introduction to the Iberian Peninsula, may already be more attenuated or 
adapted to domestic swine than African strains (Afonso et al., 1998). Viruses isolated 
from different regions will have different selection pressures e.g. when cycling of the 
virus occurs in different hosts found in Europe (domestic swine, wild boar, possibly 
ticks) versus Africa (domestic swine, warthogs, bushpigs, ticks) (O'Donnell et al., 
2015a). 
A second E-70 mutant generated by the deletion of the UK gene, a gene 
encoding for a 15-kDa protein that is highly conserved between African and European 
ASFV isolates, was significantly attenuated in domestic pigs when administered at 102 
HAD50 IM (Zsak et al., 1998). Although replication kinetics and viral yields in vitro were 
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indistinguishable from the parental strain, E-70∆UK-infected swine had viremia titers 
300- to 100,000-fold lower at 4 dpi than swine infected with the parental strain (Zsak et 
al., 1998). Swine inoculated with E-70∆UK and challenged 42 days later remained 
clinically normal with no detectable viremia (Zsak et al., 1998).  
The first description of a 9GL deletion was in ASFV Malawi Lil 20/1 using 
homologous recombination (Lewis et al., 2000). The 9GL gene encodes p14, a late non-
structural viral protein of 119 amino acids with high conservation at both the nucleotide 
and the amino acid level among several ASFV field isolates, including 22 viruses 
representative of African, European, and Caribbean strains (Lewis et al., 2000). The 
9GL gene has similarity to the Essential for Respiration and Vegetative Growth (ERV1) 
gene in yeast, which is essential for oxidative phosphorylation, the cell cycle, and the 
maintenance of mitochondrial genomes. ERV1 homologues have been found in a 
variety of organisms ranging from protozoa to plants, and in addition to ASFV, they are 
also present in a number of other cytoplasmic DNA viruses. GFER, the human homolog 
of ERV1, functions as a growth factor in the regeneration of the liver and in 
spermatogenesis (Lewis et al., 2000). Deleting the 9GL gene from ASFV negatively 
affects viral growth and virulence, but the mechanisms of this attenuation are unknown. 
The 9GL deletion reduced virus yield in swine macrophage culture by 90 to 99% 
compared to the parental strain, and a majority of the viral particles observed by 
electron microscopy resembled intermediate stages in normal virion morphogenesis. 
Based on these observations, it was speculated that p14 performs energy- and redox-
related functions in infected cells that are critical for efficient virion assembly and 
maturation (Lewis et al., 2000). 
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Swine experiments demonstrated that the deletion of 9GL in Malawi-Lil 20/1 and 
Pretoria attenuated the virus in vivo (Lewis et al., 2000; Neilan et al., 2004). Swine 
receiving 102, 104, or 106 HAD50 of Malawi∆9GL had solid protection when challenged 
with its parental isolate 42 days later. Only two swine, one each from the Malawi∆9GL 
dose groups 104 and 106 HAD50 had detectable viremia and transient fever, where as all 
4 receiving 102 had transient fever and viremia (Lewis et al., 2000). Swine inoculated 
with 104 HAD50 Pret4∆9GL and challenged 42 days post-inoculation all survived, with 
half of the swine presenting with elevated temperatures following challenge (Neilan et 
al., 2004).  
When 9GL was deleted from ASFV Georgia 2007, however, it was found that the 
mutant virus was still virulent at a dose of 104 HAD50, unlike Malawi∆9GL, which was 
attenuated at 102, 104, and 106 HAD50. Geo∆9GL at 104 HAD50 induced a lethal disease 
in swine similar to its parental isolate. Swine receiving 102 or 103 HAD50 Geo∆9GL IM 
were partially protected when challenged with Georgia 2007 at 21 and completely 
protected at 28 days post-inoculation.  
The 9GL gene deletion reduces virulence of Pretoriuskop/96/4 and Malawi Lil-
20/1 while to a lesser degree with Georgia 2007, indicating an isolate-specific effect of 
gene deletions on attenuation (O'Donnell et al., 2015b) that is of great importance for 
the design and validation of attenuated ASFV vaccines (Sanford et al., 2015).  
Similar observations were made with another set of deletion mutants. Like other 
large DNA viruses, ASFV encodes enzymes involved in the synthesis of 
deoxynucleoside triphosphates, including thymidine kinase (TK). The inactivation of the 
TK gene in poxviruses and herpesviruses showed the gene to be nonessential for 
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growth in cultured cells, but ∆TK viruses exhibited a reduction in virulence and 
pathogenicity (Moore et al., 1998). For ASFV Haiti, Malawi and Georgia, the loss of the 
TK gene severely impaired the growth on swine macrophages in vitro and reduced 
virulence in vivo (Moore et al., 1998; Sanford et al., 2015). Pigs inoculated with 104 
TCID50 of Malawi∆TK became clinically ill but 75% (3 of 4) survived, while the same 
dose of the parental virus was invariably fatal (4 of 4). For Georgia, on the other hand, 
doses of Vero-adapted Geo∆TK as high as 106 TCID50 did not lead to any clinical signs 
or viremia in pigs. At 56 dpi, the 3 surviving Malawi∆TK-inoculated swine were 
challenged intramuscularly with 104 TCID50 of the parental Malawi virus and were 
protected (Moore et al., 1998), while all Vero-adapted Geo∆TK-inoculated pigs died 
upon challenge with virulent Georgia 2007 (Sanford et al., 2015). 
ASFV contains at least five multigene families (MGF), all of which lack similarity 
to other genes and lack genetic variability among different ASFV isolates. Experiments 
have demonstrated that MGF530/360 is associated with macrophage host range 
specificity, and these genes work to promote infected cell survival (Zsak et al., 2001). 
Most recently it has been reported that deleting six genes belonging to MGF360 or 
MGF505 completely attenuated Georgia 2007, a highly virulent strain spreading through 
the Caucasus and Eastern Europe (O'Donnell et al., 2015a). One hundred percent of 
swine subsequently challenged with 103 HAD50 virulent Georgia survived (O'Donnell et 
al., 2015a). However, it was recently found that a double deletion of ∆9GL and ∆MGF 
(O'Donnell et al., 2016) was highly attenuated but did not elicit a detectable antibody 
response nor protection against challenge with the virulent parental Georgia 2007 virus. 
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Understanding the role of ASFV genes using single deletion virus mutants is very 
complex when comparing isolates. Although the NL gene deletion attenuated E75, it did 
not attenuate Malawi Lil 20/1 (Afonso et al., 1998). The 9GL deletion attenuated isolates 
Malawi and Pretoria in swine, but in Georgia at doses of 104 HAD50 the deletion did not 
attenuate the virus to prevent clinical disease and death. 
The deletion of these genes often reduces viral replication in primary 
macrophage culture and swine studies with these deletion mutants have shown that 
limiting the viral replication in macrophages dramatically reduces the virulence in 
domestic pigs. Reduced viral replication may avoid the induction of immunopathological 
processes and allow host defense mechanisms to clear the virus, but our understanding 
of how virulent or attenuated viruses interact with the host is limited. The reduced viral 
replication may allow host defense mechanisms to clear virus or it may be that some 
pathological processes are not induced. It is thought that viral replication in 
macrophages is reduced by deleting genes encoding enzymes involved in nucleotide 
metabolism such as the thymidine kinase gene and dUTPase (Dixon et al., 2008). At 
this point, the host mechanisms mediating the immune response to ASFV are not well 
understood. Further research evaluating host parameters are necessary to understand 
the early events in the replication of attenuated strains.  
 1.5 Host immune response to ASFV infections 
 1.5.1 The role of antibodies in protection 
Humoral and cellular immunity are significant components in mounting an 
immune response to ASF. It has been shown that antibodies are sufficient to protect 
swine from a lethal challenge in some early studies (Hamdy and Dardiri, 1984; Onisk et 
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al., 1994; Ruiz Gonzalvo et al., 1986b). In a study by Zsak et al., convalescent serum 
from pigs infected with a low virulent isolate from Spain E75, neutralized culture 
adapted variants E75, E70, Lisbon60, Malawi Lil20/1 and a low passage variant of E75 
by 86-97% in Vero and macrophage cell cultures (Zsak et al., 1993). It was also found 
that a monoclonal antibody, mAb-135D4, recognizing ASFV protein p72, also exhibited 
strong neutralizing activity with these viruses (Zsak et al., 1993). Ruiz et al. 
demonstrated that sera from pigs inoculated with attenuated isolates and later 
challenged with a heterologous isolate inhibited infection of PBMCs by different 
heterologous viruses (Ruiz Gonzalvo et al., 1986b). 
Based on results from early experiments, it was hypothesized that neutralizing 
antibodies were not completely effective or even induced by ASFV (Hess, 1981; 
Vinuela, 1985). However, it was demonstrated that different isolates of ASFV could be 
neutralized by convalescent swine sera and monoclonal antibodies (Ruiz Gonzalvo et 
al., 1986a; Ruiz Gonzalvo et al., 1986b; Zsak et al., 1993). These authors described a 
persistent fraction of non-neutralized virus of 10% in their assays.  
Other roles for antibodies should be considered. Both Onisk and Wardley et al. 
examined the role of antiviral antibodies by passive antibody transfer experiments within 
a homologous system (Onisk et al., 1994; Schlafer et al., 1984b; Wardley et al., 1985). 
These studies observed a reduction in virulence, mortality, and a delayed onset to 
infection in pigs treated with anti-ASF immunoglobulin. Passive transfer of antibodies to 
naïve pigs could provide protection against a virulent challenge. Protective antibodies 
are known to function in virus neutralization, antibody-dependent cell-mediated 
cytotoxicity (ADCC), and complement-dependent cell lysis (CDCL) (Wardley et al., 
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1985; Wardley and Wilkinson, 1985). A reduction in viremia is only secondary to the 
clinically protective effects of antibody as viremia levels and survival appear to show 
little correlation (Wardley et al., 1985).  
Our understanding of neutralizing antibodies is limited. Previously it was shown 
that antibodies transferred by colostrum provided a degree of protection to suckling 
piglets against virus challenge (Schlafer et al., 1984a; Schlafer et al., 1984b). Piglets 
given colostrum collected from a sow that had recovered from ASFV infection or Ig 
precipitated from ASFV antiserum had a delayed onset of clinical disease and viremia. 
Piglets fed passively transferred antibodies from the colostrum of recovered pigs or by 
parental administration of antiserum had 10,000-fold lower viremia titers than the naïve 
control piglets (Schlafer et al., 1984b). In this study 9/10 swine given colostrum from 
ASFV recovered swine survived virulent challenge (Schlafer et al., 1984b). 
Onisk et al. reported that 85% of swine receiving anti-ASFV immunoglobulin (Ig) 
survived challenge, had a 3-day delay in viremia and a 10,000-fold reduction in mean 
and maximum virus titers. This is one of few studies reporting direct in vivo evidence 
where the acquisition of humoral protective immunity by naïve pigs against ASFV was 
achieved after passive transfer of ASFV-specific antibodies obtained from pigs 
previously infected with attenuated ASFV (Onisk et al., 1994). 
Blocking antibodies can inhibit neutralization and allow for the persistence of a 
small fraction of non-neutralized virus. This phenomenon was found by other groups 
(Ruiz-Gonzalvo et al., 1996; Zsak et al., 1993). It is thought that incomplete 
neutralization of ASFV could lead to chronic ASFV infection in pigs and possible 
persistence of the virus in swine in the situation of an excess of antibodies. One group 
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demonstrated a long-term persistent ASF infection of 100% of domestic swine infected 
for more than 500 days post-inoculation (Carrillo et al., 1994). This subject of persistent 
infections and the role of antibody neutralization in ASF infections need further 
investigation. 
Gomez-Puertas et al. showed that ASFV induces antibodies that neutralize the 
virus before and after binding to susceptible cells, inhibiting both virus attachment and 
internalization. He showed that antibodies to p72 and p54 are involved in the inhibition 
of virus attachment, while antibodies to p30 inhibited virus internalization in Vero cells 
and macrophages (Gomez-Puertas et al., 1996). Later it was shown that neutralization 
by specific antibodies depends on the phospholipid composition of the viral particle 
(Gomez-Puertas et al., 1997).  
However, the role of these proteins in a protective immune response in swine 
could not be demonstrated when pigs were immunized with baculovirus-expressed p30, 
p54, p72, and p22 from Pret4 (Neilan et al., 2004). Specific neutralizing antibodies could 
be detected in immunized animals but clinical disease ensued with swine dying between 
7 and 10 dpc. Pigs immunized with baculovirus-expressed recombinant proteins yielded 
contradictory results in regards to protection against virulent challenge (Gomez-Puertas 
et al., 1998; Neilan et al., 2004). It is possible that these results are due to differences in 
viral stains used. Antibodies certainly play a significant role in protection against ASF, 
but other active components of the immune response including the cellular immunity 
should be considered. 
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 1.5.2 Role of cellular immunity in protection 
African swine fever virus productively infects macrophages, causes apoptosis in 
lymphocytes and encodes a variety of immune invasion genes. Cellular immune 
responses to ASFV infection have been detected and quantified, but whether they are 
critical in protection against clinical disease still remains to be elucidated.  
Proliferation of ASFV-specific lymphocytes was initially reported by (Wardley and 
Wilkinson, 1980) 10 days after infection with a non-virulent Uganda isolate, but not with 
a virulent Kiurawira isolate because swine died 5 to 10 after inoculation. Scholl et al. 
similarly showed a strong antigen-specific blastogenic response in PBMCs of swine 
infected with an attenuated strain of ASFV (NH/P68) (Scholl et al., 1989). 
Later experiments examined the function of ASFV-specific cytotoxic CD8+ T 
lymphocytes (CTL). Martins et al. showed MHC class I restricted CTL activity against 
ASFV-infected cells in swine infected with the non-fatal, non-hemadsorbing ASFV 
isolate NH/P68 (Martins et al., 1993).  
The cellular immune recognition of peptides expressed by a random genomic 
library of ASFV Malawi (LIL20/1) was studied to better understand the targets of that 
cellular immune response. The viral DNA was randomly sheared, cloned into plasmids 
and expressed in skin fibroblasts to serve as antigen presenting cells. Each clone was 
screened for recognition by matched CD8+ lymphocytes from ASFV-sensitized swine, 
and T cell proliferation was detectable for 14/72 clones (Jenson et al., 2000). 
The importance of CTLs for protection against virulent ASFV was demonstrated 
by the depletion of CD8+ cells in swine vaccinated with the non-pathogenic OUR/T88/3 
variant (Oura et al., 2005). This depletion abrogated protection against challenge with 
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the related virulent isolate OUR/T88/1, indicating that CD8+ lymphocytes play an 
important role in the protective immune response to ASFV infection and that antibody 
alone is not protective. 
This was confirmed by the observation that pigs that remained asymptomatic 
after infection with NH/P68 developed high levels of natural killer (NK) cells and resisted 
subsequent challenge with virulent ASFV Lisbon 60. Pigs that developed lesions after 
NH/P68 infection, on the other hand, had normal NK cell counts but developed high 
titers of ASFV-specific antibody (Leitao et al., 2001) 
IFN-γ, predominantly produced by NK cells and effector T cells, is an activator of 
the effector functions of monocytes and macrophages. Activation of macrophages by 
IFN-γ enhances direct antimicrobial activity and proinflammatory responses, including 
cytokine and chemokine production, and promotes further IFN-γ production at the site of 
inflammation. Considering that ASFV mainly targets professional APCs, IFN-γ might 
have a direct impact on virus-host interactions, especially during the early stages of 
infection (Takamatsu et al., 2013). 
Esparza et al. were among the first to demonstrate the reduction of ASFV 
replication in monocytes and alveolar macrophages by bovine IFN-α and porcine IFN-γ 
(Esparza et al., 1988). Paez et al. demonstrated that human IFN-α and IFN-γ inhibited 
ASFV replication in Vero cells (Paez et al., 1990). They also found that continuous 
treatments with IFN-α “cured” Vero cells from persistent infections with ASFV.  
A few studies investigating IFN-γ production in swine PBMCs after exposure to 
vaccine and/or mutant virus studies exist. In one of the first studies, PBMCs from swine 
immunized with attenuated, Vero-cell adapted ASFV BA71 proliferated and produced 
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interleukin-1 (IL-1) and IFN-γ after homologous restimulation in vitro (Revilla et al., 
1992).  
Two reports (Argilaguet et al., 2012; King et al., 2011) state that there is a direct 
correlation between circulating IFN-γ-producing PBMCs and protection against virulent 
challenge in animals. However, our studies outlined in this dissertation with attenuated 
viruses including ∆9GL Pretoria and ∆9GL-UK Georgia have demonstrated no 
correlation between IFN-γ-producing PBMCs in vaccinated animals and protection 
against virulent challenge. 
For these reasons, we looked into measuring other cytokines, chemokines, or 
immune mediators to find host response parameters that could be correlated with swine 
surviving virulent challenge. 
 1.5.3 Cytokines in ASFV infection 
ASFV infects macrophages, which are antigen-presenting cells (APCs) that play 
an important role in the immune system. APCs detect pathogen-associated molecular 
patterns (PAMPs) through their array of pattern recognition receptors (PRRs), including 
toll-like receptors (TLRs), and produce cytokines and chemokines, which aid in 
signaling to clear pathogens by phagocytosis. Macrophages are essential components 
of the host defense system, but their activation must be controlled since the cytokines 
and mediators they produce can lead to host tissue damage. 
ASFV encodes over 150 proteins, many of which have been shown to modulate 
host immune responses (Dixon et al., 2004; Tulman et al., 2009). ASFV has proteins 
that inhibit interferon induction, host transcription factor activation, stress responses and 
apoptosis. During ASFV infection, changes occur in coagulability and vascular 
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permeability due to alterations in chemokine secretion that play a role in disease 
pathogenesis (Gomez del Moral et al., 1999; Salguero et al., 2002; Salguero et al., 
2005). 
Not all immune responses contribute to protective immunity, and some of these 
responses contribute to pathological changes in ASFV-infected swine. In our research 
we attempted to decipher the role of different cytokines in mediating protection against 
ASF.  
To date there are only a limited number of in vivo studies reporting on the 
cytokine response in swine infected with attenuated strains of ASFV, and they report 
conflicting results. In vitro data has shown that non-virulent strains (NH/P68, 
∆MGF360/530 Pretoria) induce higher levels of monocyte chemoattractant protein 
(MCP-1), CXCL10, IFNα, IL-6, IL-12p40, IL-15 and TNFα when compared to their 
virulent (Lisbon 60, Pret4, E75) counterparts by PCR or microarray analysis (Afonso et 
al., 2004; Gil et al., 2003; Gomez del Moral et al., 1999).  
TNFα has been considered as a major player in the clinical manifestation of ASF. 
Gomez del Moral found that tissue macrophages appeared to be the main source of 
TNFα in spleen and lymph nodes of ASFV-infected animals. This increase in TNFα was 
correlated with the expression of viral genes encoding p30 or p54 (Gomez del Moral et 
al., 1999). Interestingly, Esparza reported that bovine tumor necrosis factor α (TNF-α) 
increased ASFV production in monocytes (Esparza et al., 1988). 
 In swine infected with virulent ASFV, concentrations of TNFα increased at 3 to 4 
dpi and remained elevated until death. It has been suggested that the coagulation and 
vascular disorders seen in ASFV infection are not due to a direct effect of the virus, but 
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due to factors released by infected macrophages. TNFα affects endothelial cells, 
ultimately decreasing anticoagulation, increasing permeability and expression of 
adhesion molecules for leukocytes and platelets. 
TNFα has also been attributed to inducing apoptosis of surrounding cells, and a 
component of shock as a stimulator of IL-1 and IL-6. IL-12p40 and IFNα/β are secreted 
after in vitro infection with non-virulent isolates, while TNFα is secreted after infection by 
both non-virulent and virulent isolates (Afonso et al., 2004; Gil et al., 2008; Gil et al., 
2003; Gomez del Moral et al., 1999; Zhang et al., 2006). 
MCP-1 attracts monocytes and promotes mast cell activation, and CXCL10 also 
attracts monocytes, T lymphocytes, and NK cells while having the capacity to control 
viral replication. In Afonso et al., it was also found that the attenuated ∆MGF360/530 
Pretoria virus induced the expression of the interferon-stimulated genes ISG15 and 
ISG43 (Afonso et al., 2004). ISG15 stimulates the production of IFN-γ by CD3+T cells to 
enhance the proliferation and cytotoxicity of NK cells (Zhang and Zhang, 2011), while 
ISG43 is a protease whose function is to specifically remove ISG15.  
Infection of blood-derived macrophages with low (OURT88/3) and high virulence 
(Benin 97/1) ASFV isolates results in the down-regulation of mRNA levels of 
chemokines CCL2, CCL2L, CXCL2, and chemokine receptors CCR1, CCR5, CXCR3, 
CXCR, and the up-regulation of CCL4, CXCL10, and chemokine receptor CCR7. 
Macrophages infected with low-virulence isolated had higher mRNA expression of 
CCL4, CXCL8, and CXCL10 (Fishbourne et al., 2013a).  
These parameters were further investigated in blood from pigs infected with low 
(OURT88/3) and high virulence (Benin 97/1) ASFV isolates (Fishbourne et al., 2013b). 
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CCL2 mRNA was increased in swine infected with Benin 97/1 by 30-fold compared to 
those infected with OURT88/3, the opposite of what was found in vitro. CCL2, which is a 
chemoattractant for macrophages, may increase monocyte recruitment from the bone 
marrow. An increase in CCL2 could represent a mechanism by the virus to attract 
susceptible cells to an area of infection in order to increase viral dissemination.  
In the same study, CXCL10 mRNA was increased by up 15-fold compared to 
naïve swine. CXCL10 is an interferon-stimulated gene. It has an important role during 
viral infections, and may contribute to lymphocyte priming toward Th1, promote the 
survival and expansion of T lymphocytes and induce apoptosis in lymphocytes lacking 
specific co-stimulating signals (Fishbourne et al., 2013b).  
Overall, the diversity of findings emphasizes that the virulence of ASFV isolates 
may be dependent on their capacity to regulate the expression of macrophage-derived 
cytokines that influence the development of protective host responses. The differences 
in cytokine expression between virulent and non-virulent isolates suggest the action of 
viral factors capable of regulating the cytokine expression at the macrophage level. 
Such interactions are highly relevant to understanding ASF pathogenesis and protective 
responses against infection. 
 1.6 Summary and rationale for the studies 
 1.6.1 Significance of our work 
ASF is a severe, multi-systemic, hemorrhagic viral disease that threatens the 
swine economy globally. ASF is enzootic to most countries of Sub-Saharan Africa. 
Since 2007, ASF has been reported in Russia, Ukraine, and Belarus. In 2014 it entered 
the European Union and still currently affects the Baltic region and Poland. Since the 
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entry of ASF into the European Union, there is a constant risk for ASF to continue its 
spread throughout Europe and globally. Currently no vaccine is available to prevent 
ASF, and control measures are limited to culling of infected swine and restricted animal 
movement.  
With no vaccines available, it is critical that we improve our understanding of the 
protective immune response against ASFV. No subunit vaccine has induced 100% 
protection, and over the years several attenuated strains have been developed. 
Specifically, individual deletions of UK (DP69R), 23-NL (DP71L), TK (A240L), 9GL 
(B119L), or multiple genes from MGF 530/505 and MGF 360 from the genomes of 
virulent ASFV viruses including Malawi Lil-20/1 (Mal), Pretoriuskop/96/4 (Pret4), E70 
and Georgia 2007 resulted in significant attenuation of these isolates in swine (Lewis et 
al., 2000; Moore et al., 1998; O'Donnell et al., 2015a; O'Donnell et al., 2015b; Zsak et 
al., 1998; Zsak et al., 1996). 
Pigs immunized with live attenuated ASFVs containing genetically engineered 
deletions of specific virulence-associated genes are generally protected when 
challenged with homologous parental viruses. Nevertheless, there are gaps of 
knowledge in understanding the complex virus-host interaction, the role of humoral 
immunity, and the significance for T-cell immunity in protective vaccination against 
ASFV. 
 1.6.2 Why we chose Pretoria ∆9GL for this model 
The animal model described in this thesis uses swine inoculated with an 
attenuated strain, Pret4∆9GL, challenged with the parental Pret4 at different times post-
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vaccination. Swine were infected with Pret4Δ9GL virus and challenged with the virulent 
parental Pret4 virus at different times post-inoculation (7, 10, 14, 21, and 28 dpi).  
We chose ∆9GL Pretoria for multiple reasons. Pret4∆9GL is a well-established 
ASFV deletion mutant that has been used in earlier studies (Lewis et al., 2000; Neilan et 
al., 2004). Those experiments demonstrated that the deletion of 9GL from ASFV Malawi 
and Pretoria attenuated the virus in swine. One of the first experiments demonstrated 
that swine inoculated with 104 HAD50 Pret4∆9GL and challenged at 42 days post-
inoculation were protected with half of swine showing no fever following challenge 
(Neilan et al., 2004).  
Previous research has shown much success with attenuated strains obtained 
naturally, by adaptation to cell cultures, or by genetic modifications as effective 
experimental vaccines that protect against homologous strains. Currently there is no 
strong understanding of the host immune mechanisms mediating protection in swine 
immunized with attenuated strains.  
The Pret4∆9GL virus was previously generated by homologous recombination 
(Lewis et al., 2000; Neilan et al., 2004). The 9GL gene deletion reduces virulence and 
replication in cell culture (Lewis et al., 2000). The 9GL gene has similarity to Essential 
for Respiration and Vegetative Growth (ERV1) in yeast. Although the specific 
mechanism in how the 9GL deletion attenuates ASFV in swine is unknown, the deletion 
causes defects in virion assembly and maturation as well as causing viral interference in 
vivo (Lewis et al., 2000).  
We selected the Pret4 isolate since it was less virulent than Georgia 2007 or 
Malawi Lil 20/1 and we hypothesized that Pret4∆9GL would not be a strong 
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immunogen. This increased our chances of obtaining protected and unprotected 
individuals by the same treatment, cumulating the chances of identifying host 
mechanisms and protection with groups of animals receiving the same treatment at 
different time points. Within this model, we sought to identify host immune mechanisms 
(virus specific antibodies, IFN-γ responses in ASF-stimulated PBMCs, and patterns of 
systemic cytokines) that could be associated with presence of protection. With this 
challenge model, we were able to observe and evaluate early protection of swine 
against ASF, while also providing an opportunity to understand different host immune 
mechanisms that may take place as early as 7-14 days post-inoculation and later at 21-
28 days post-inoculation.  
 1.6.3 Cross validation of Pretoria ∆9GL with Georgia ∆9GL/∆UK swine 
studies 
To further extend our knowledge and cross-validate our results, this 
vaccination/challenge model was also utilized with a double-deletion mutant of Georgia 
2007, Geo∆9GL∆UK, and its parental strain.  
Deletion of the 9GL (B119L) gene from ASFV Malawi Lil-20/1 and 
Pretoriuskop/96/4 attenuated both viruses in swine and provided a protective immune 
response against lethal challenge with parental isolates. However, the Δ9GL version of 
the Georgia isolate (ASFV-G), although still attenuated, had to be administered at low 
doses (102 to 103 HAD50) to induce a protective response and not cause clinical signs in 
inoculated swine while still inducing a protective response. In order to attenuate 
GeoΔ9GL further, our lab deleted a second gene, UK (DP96R), which had previously 
been shown to attenuate ASFV E70. Swine inoculated with Geo∆9GL∆UK and 
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challenged at 14 and 28 days post-inoculation had 100% survival (5/5 and 10/10). With 
this model we also investigated immune factors associated with early protection at 7 to 
14 days post-inoculation and later onset at 21 and 28 days post-inoculation and 
compared the results to those of the Pret4Δ9GL model. 
 1.6.4 Goals of this research 
In this thesis we focused on studies to find correlates of protection against ASFV. 
The animal model described in this thesis used swine infected with attenuated, deleted 
mutant and virulent wildtype strains.  
Our first aims were to compare growth curves in vitro while also investigating the 
replication and pathogenesis of Pret4 versus Pret4∆9GL virus in vivo. We compared 
viral replication with a growth curve over a four-day period in primary swine macrophage 
culture. Next we investigated differences in the replication of these two viruses in swine. 
We compared the clinical outcome of infection (fever, mortality) between Pret4 and 
Pret4∆9GL. Following clinical examination, we compared the level of viremia and nasal 
shedding in swine infected with either virus and analyzed differences in early viral 
replication in tissues collected from swine at 2,4, 6, 8, and 10 days post-inoculation. 
Our next aim was to generate information to explain dynamics of protection, 
optimize our detection of immune responses, while increasing our knowledge in the 
design of a rational vaccine using a rationally attenuated mutant. In order to detect 
different elements of immunes response associated with swine protected from virulent 
challenge, samples were taken at the time of challenge of 114 vaccinated swine with 65 
from the Pret4∆9GL group and 54 from the Geo∆9GL∆UK group. In this model, 
antibody was measured via immunoperoxidase and ELISA, and IFN-γ was quantified by 
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ELISPOT with stimulated PBMCs. Circulating cytokines were measured in swine sera at 
the time of challenge.  
Time-course antibody data were also collected from the start of the study until 21 
days after challenge to characterize seroconversion and our ability to measure it with 
our in-house anti-ASFV IgG ELISA and immunoperoxidase assays. Within the groups of 
animals inoculated with Pret4∆9GL, IFN-γ responses in ASFV-stimulated PBMCs were 
characterized one week before challenge, at challenge, and one week after challenge in 
all 65 inoculated animals. To further supplement this information in determining host 
factors critical for the induction of a protective immune response against lethal 
challenge, 18 cytokines were tested in swine sera at the time of challenge. These 
cytokines included MCP2, TGF-β1, IFN-α, IFN-β, IFN-γ, IL1-α, IL1-β, IL-2, IL-5, IL-8, IL-
10, IL-12 p35, IL-12 p40, OAS, PKR, TNF, MX-1, and VCAM using commercial ELISAs. 
The existence of correlates of immunity and protection against ASF still remains 
controversial. The determination of these correlates is a critical step in the development 
of a vaccine strategy against ASFV as it provides different criteria to understand the 
host’s immune response. The use of attenuated ASFV strains generated by genetic 
manipulation is a reasonable approach as model to investigate protective immune 
responses and to develop an effective ASFV vaccine.  
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Chapter 2 - Materials and Methods 
 2.1 Introduction 
Since common methods were used in many of the experiments described in this 
dissertation, this chapter provides the collected technical approaches and research 
material used to avoid unnecessary duplication. 
 2.2 Viruses used in these studies 
As shown in Table 2.1, multiple viruses were used from the experiments 
described in this dissertation. The preparation of these viruses, including the generation 
of deletion mutants is described in below. Further details of the viruses and rationale 
and their selection are provided in chapter 1. 
Table 2.1 Viruses and their characteristics 
Isolate Gen Bank 
no. 
Genotype 
(P72 
basis) 
Source Phenotype 
Pretoriuskop/96/4 
(Pret4) 
AY261364 1 Tick 
South Africa 
1996 
Highly virulent (lesser 
compared to Geo) 
Pret4∆9GL  1 Macrophage 
culture 2004 
Attenuated by deletion 
of B119L 
Georgia 2007/1 
(Geo) 
FR682468 2 Domestic pig 
Georgia 
2007 
Highly virulent 
Geo∆9GL/∆UK  2 Macrophage 
culture 2016 
Attenuated by deletion 
of B119L and DP96R 
 
 2.2.1 Primary culture of macrophages 
Healthy donor swine older than eight months were bled one to two times per 
month to obtain PBMCs for primary culture. The blood was collected using 4-6 inch 12-
14 gauge stainless steel needles via the right jugular vein with a vacuum pump and 
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tubing primed with heparin. At each collection, 1-2 liters of blood containing 50 ml/l of 
heparin were harvested. 
Primary swine macrophage cultures were prepared from defibrinated blood as 
described by Zsak et al (1996). The blood was incubated at 37°C for 1-2 hours until the 
erythrocytes sedimented to the bottom and almost half of the total volume was retained 
as plasma resting at the top. In up to 25 parallel preparations, 35 mL of plasma were 
underlaid with Ficoll-Paque Plus at a specific density of 1.077 g/ml. Plasma and Ficoll 
were spun at 400 × g for 30 minutes at room temperature with brake and acceleration 
set to zero. After centrifugation, the cell-free plasma was collected and spun again to 
remove remaining cells and debris, filtered through 0.45μm and 0.22μm filters and 
stored at 4°C. Mononuclear leukocytes from the plasma-Ficoll interface were pipetted 
into new 50-mL conical tubes and washed twice with RPMI-1640 media containing 1% 
antibiotics and antifungal agents. 
The washed cells were then seeded into 20-25 75 cm2 filter-cap flasks (Primaria) 
containing macrophage media composed of RPMI, 30% (v/v) L929 cell supernatant, 
20% (v/v) fetal bovine serum, 1% antibiotics and 0.1% gentamicin. The flasks were 
incubated for 24 hours at 37°C with 5% CO2. On the following day, adherent cells (i.e., 
macrophages) were detached from the flasks using 10mM EDTA in sterile phosphate-
buffered saline (PBS) and reseeded into 6- and 96-well plates (Primaria) at a density of 
1X105 cells per well in 96-well plates and 2X107 per well in 6 well plates for use in 
assays 24 hours later. 
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 2.2.2 Homologous recombination 
 2.2.2.1 Pretoria 
Pretoriuskop/96/4 (Pret4) and its attenuated isolate containing a deletion of the 
9GL gene (B119L) Pret4∆9GL were kindly provided by Dr. John Neilan (Neilan et al., 
2004) of the Plum Island Animal Disease Center. Recombinant ASF viruses were 
generated by homologous recombination between the parental ASFV genome and a 
recombination transfer vector after infection and transfection of primary swine 
macrophage cultures (Lewis et al., 2000; Neilan et al., 1997; Zsak et al., 1996). The 
Pretoria ∆9GL (Pret4∆9GL) virus was derived from the Pretoriuskop/96/4 isolate of 
ASFV by deleting 173 bp within the 9GL (B119L) gene encompassing amino acid 
residues 11-68  (Lewis et al., 2000; Neilan et al., 2004). The deleted region was 
replaced with a gene cassette containing the β-glucuronidase (β-GUS) gene and an 
ASFV p72 promoter sequence via homologous recombination when macrophage 
cultures were infected with ASFV Pret4 and subsequently transfected with 
p72GUSΔ9GL. Recombinant Pret4Δ9GL viruses were purified by plaque purification. 
 2.2.2.2 Georgia 
Geo∆9GL/UK was derived from the highly virulent Georgia 2007 (Geo 2007) 
isolate of ASFV by two successive homologous recombination procedures. First, a 173 
bp region within the 9GL gene was deleted from the Geo 2007 virus as described above 
and replaced with the p72GUS∆9GL reporter cassette. The single-deletion mutant was 
obtained after a series of plaque purifications on primary swine macrophage cultures 
(O'Donnell et al., 2015b). The second recombination step replaced the UK gene (Zsak 
et al., 1998) with a cassette containing a fluorescent gene (mCherry) under the control 
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of the p72 promoter. This recombinant virus was also plaque purified and amplified in 
primary swine macrophage cultures. 
Figure 2.1 Homologous Recombination, targeted gene deletion for ASFV 
attenuation 
 
 2.2.3 Sequencing 
ASFV DNA was extracted from infected macrophage cultures by Trizol, 
quantified with the Qubit® dsDNA HS assay kit and enzymatically fragmented using the 
Ion ShearTM Plus kit. Fragmented DNA was barcoded using the Ion Plus Fragment 
Library kit, size selected, and the DNA library was clonally amplified onto Ion Sphere™ 
Particles, generating template-positive ISPs using the Ion PGM™ Template 
OneTouch™ 2 200 Kit with the Ion OneTouch™ 2 Instrument. The template-positive 
ISPs were prepared for sequencing, loaded onto an Ion 314™ Chip v2 and run on the 
Ion PGM™ Sequencer. Obtained sequences were trimmed using the Galaxy 
(https://usegalaxy.org/) NGS QC workflow, then aligned and analyzed using 
Sequencher 5.2.2 (Genecodes) and CLC Genomics Workbench (Qiagen).  
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Figure 2.2 Next-Generation Sequencing (NGS) of Pretoria Genome 
 2.2.4 Growth curves in vitro 
Pret4 and Pret4∆9GL were titrated on primary swine macrophages. The 
presence of virus was assessed by hemadsorption. Virus titers were calculated by the 
method of Reed and Muench (Reed and Muench, 1938) and expressed as 50% 
hemadsorption doses (HAD50). For the growth curves, preformed monolayers of primary 
swine macrophages in 6-well plates were infected at a multiplicity of infection (MOI) of 
0.01 HAD50 per cell. Virus was adsorbed for 1 hour at 37°C with 5% CO2. The inoculum 
was removed and cells were rinsed two times with PBS before 2 mL of macrophage 
media were added to each well. The supernatant from one of the 6 wells on the plate 
was collected after 0, 2, 24, 48, 72, and 96 hours of incubation at 37°C with 5% CO2. 
Supernatants were frozen at -70°C, and all samples were titrated at the same time to 
avoid inter-assay variability. Viral titration was performed on primary swine macrophage 
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cell culture in 96-well plates. Virus dilutions and cultures were performed using 
macrophage media. 
 2.3 Viral detection assays from swine studies 
 2.3.1 Virus isolation and titration 
Primary swine macrophages were seeded on 96-well plates at a density of 1X105 
cells per well in a volume of 100 µl. For the titrations, 96-well deep-well plates were 
filled with 630 µl of macrophage media per well. In the top row of the deep-well plate, 70 
µl of thawed whole blood were added to the media, creating a 1/10 dilution. The blood 
and media were mixed by pipetting up and down 10 times, and 70 μl were transferred to 
the next row. This was repeated five more times to create a dilution series with seven 
steps, from 10-1 to 10-8. Tips were changed before transferring each new dilution to the 
next row. All samples and plates were kept on ice to prevent blood from clumping. After 
the dilutions had been prepared, 100 µl of each dilution were transferred to the 96-well 
plates containing the macrophages in replicates of four, with each plate of macrophages 
receiving a total of 3 titrated samples. 
 
Figure 2.3 Virus titration and dilution scheme 
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 2.4 Animal experiments 
For all ASFV experiments castrated male Yorkshire pigs were purchased from a 
herd free of porcine reproductive and respiratory virus. Swine were dewormed and 
vaccinated against common porcine pathogens, including porcine circovirus 2, prior to 
arrival on Plum Island. Pigs were approximately 3-4 months old and weighed 33-36kg 
on arrival. All animal procedures were performed following a protocol approved by the 
Plum Island Animal Disease Center Institutional Animal Care and Use Committee 
(IACUC), ensuring ethical and humane treatment of experimental animals. The animal 
experiments were carried out in BSL-3 Ag isolation rooms at the Plum Island Animal 
Disease Center. Animals were kept within the facilities for at least 5 days prior to the 
start of the experiments to allow for acclimation to the new environment. All animals 
were fed a grower diet daily and had unlimited access to water. 
Swine were clinically assessed, with rectal temperatures recorded at least once 
per day. Moribund animals were sedated with an intramuscular injection of tiletamine 
hydrochloride and zolazepam hydrochloride (Telazol, Zoetis; 3 mg/kg), ketamine (8 
mg/kg), and xylazine (4 mg/kg), placed in dorsal recumbency and humanely euthanized 
intravenously via the right jugular vein with 85.8 mg/kg of sodium pentobarbital. Animals 
without clinical disease were humanely euthanized at the end of the study at 21 days 
post-challenge. 
 2.4.1 Clinical evaluation of swine 
A clinical score was calculated for each pig in the comparative pathogenesis 
study to compare differences in swine responses to the Pret4∆9GL and Pret4 viruses. 
Clinical signs and scoring are found in Table 2 below. The clinical signs were assigned 
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numerical values based on severity and significance as described by (Howey et al., 
2013). Clinical scores were recorded daily for each pig. 
Table 2.2 Clinical Scoring of swine inoculated with ASFV adapted from (Howey et 
al., 2013) 
Characteristic Score  
Behavior and Mentation: 0 Normal, alert, responsive 
 1 Mildly obtunded. Slightly reduced liveliness, stands 
up unassisted, resists restraint or rectal 
thermometer 
 2 Obtunded. Reluctant to stand but will do so when 
assisted, decreased resistance to restraint or rectal 
thermometer 
 3 Intermittent ataxia, disorientation, can still 
stand/walk or Will not stand/walk even when 
assisted, still conscious 
 4 Moribund. Nonambulatory, 
unconscious/nonresponsive 
Neurologic signs   
 0 Normal 
 2 Unambiguous neurologic signs, convulsions, 
seizures 
Defecation   
 0 Normal to mildly soft stools 
 1 Profuse watery diarrhea +/- mild hematochezia or 
melena 
 2 Severe to marked hematochezia or melena 
Body Temperature   
 0 38-40°C 
 1 Temperature greater than or equal to 40°C 
 2 Temperature greater than or equal to 40°C for at 
least 2 subsequent days 
 3 Temperature greater than or equal to 41°C 
 4 Temperature than or equal to 38°C 
 
 2.4.2 Sample collection 
Swine were restrained by a rope. Sample collection included whole blood with 
EDTA for titrations and PCR analysis, whole blood with heparin for ELISpot, and clotted 
blood for serum for ELISA (Enzyme Linked Immunoassay), IPA (Immunoperoxidase 
Assay), and cytokine ELISAs. All blood samples were collected from the jugular vein. 
Nasal swabs were collected from both nostrils using sterile cotton swabs that extended 
 56 
just caudal of the alar fold. All samples were stored in cryovials and kept at -70°C until 
processing. 
 2.4.3 Comparative pathogenesis study with Pret4 and Pret4∆9GL 
Experiments were performed to compare pathogenesis between swine 
inoculated with virulent Pret4 and Pret4∆9GL via intramuscular inoculation. Twenty pigs 
were inoculated into the right semimembranosus muscle with 104 50% hemadsorption 
doses (HAD50) of virulent Pret4 or Pret4∆9GL in 1 mL (two groups, n=10 per group). 
Swine were evaluated daily for fever and clinical signs. Blood samples and nasal swabs 
were collected every other day for 10 days post-infection (DPI). Two animals from each 
group were euthanized and necropsied 2, 4, 6, 8, and 10 days post-infection. Tissues 
collected during postmortem examination included tonsil of the soft palate, lingual tonsil, 
nasal tonsil, dorsal nasopharynx, lung, liver, spleen, as well as retropharyngeal, 
gastrohepatic, and superficial cervical lymph nodes. 
Tissue samples collected were stored in cryomolds, embedded in Optimal 
Cutting Temperature (OCT) medium (Tissue-Tek O.C.T. compound, Sakura Finetek, 
CA) and then frozen in liquid nitrogen vapor. 
 2.4.4 Protective immunity after vaccination with Pret4∆9GL: onset of 
protection 
Eighty-five pigs were used in a second set of experiments to assess the onset of 
protective immunity against virulent homologous challenge after vaccination with 
Pret∆9GL. Sixty-five swine were inoculated with 1 mL 104 HAD50 of Pret4∆9GL and 
subsequently challenged with 1 mL 104 HAD50 of virulent Pret4 at 7, 10, 14, 21, or 28 
days post-inoculation. The experiments were carried out in 4 batches, and each 
 57 
challenge time point was repeated at least once. In each experiment, the Pret4∆9GL 
inoculations were staggered so that all groups were challenged with Pret4 at the same 
time. A control group of 5 naïve swine was included in each batch; overall, 20 swine 
were used as unvaccinated challenge controls. Each vaccination group contained 5 
swine, with the exception of the 28-day challenge where the first experiment contained 
four swine and the third contained six swine. 
 2.4.5 Protective immunity after vaccination with Geo∆9GL/UK: dose effect 
and onset of protection 
At total of sixty-four swine were used in a third set of experiments with the 
Georgia strain of ASFV. This included 15 naïve controls for three separate challenge 
experiments and 49 vaccinates receiving the double deletion mutant Geo∆9GL/UK 
before challenge with virulent homologous Georgia 2007. For the dose study, groups of 
4 or 5 swine were vaccinated with either a low dose of 102 HAD50 (two experiments, n = 
9 overall), a medium dose of 104 HAD50 (two experiments, n = 10), or a high dose of 106 
HAD50 of Geo∆9GL/UK (three experiments, n = 15). All vaccinated swine were 
challenged with 104 HAD50 of virulent Georgia intramuscularly at 28 days post-
inoculation with Geo∆9GL/UK. For the onset of protection study – similar to what was 
described for Pret4∆9GL above – 15 pigs (in 3 groups of 5) were inoculated with the 
medium dose of Geo∆9GL/UK (104 HAD50) and challenged with virulent Georgia 2007 
at 7, 14 or 21 days post-inoculation.  
 2.5 Tissue maceration technique for virus isolation 
Ten tissues were collected from 20 swine that were infected with either 
Pret4∆9GL or Pret4 during necropsy and frozen at -70°C. Tissues weighing 1 gram or 
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less were used for titration. Each tissue was place in an individual mortar with a small 
pinch of aluminum oxide (Ward’s Science, Rochester NY) and ground to a paste with a 
pestle. For every 0.5 g of tissue 1 mL of DMEM with 10% FBS was added to the tissue 
paste. The tissue was ground further with media and pipetted into 2 mL microcentrifuge 
tubes and centrifuged for 10 minutes at 4°C at 8,000 × g. Supernatant from the tissue 
macerate was used for titrations as described previously. 
 2.6 PCR for detection and typing of Pret4 and Pret∆9GL 
Total DNA was extracted from 200 μl of whole blood from infected swine or virus 
stocks with the Qiagen DNeasy blood and tissue kit, using 20 μl proteinase K and 
200 μl buffer AL. For improved lysis, blood samples were incubated at 56°C for 10 min, 
but this was not done for the virus stocks. 
After lysis, 200 μl of 100% ethanol were added and the samples were mixed 
thoroughly by vortexing. The mixture was transferred into a DNeasy Mini spin column in 
a 2-mL collection tube, centrifuged at 6000 × g for 1 min and the flow through was 
discarded. Washes with AW1 and AW2 were completed in a similar manner following 
the manufacturer’s protocol. DNA was eluted with 50 μl of nuclease-free water at 
6000 × g for 1 min. 
Identification of virus in the blood of infected/challenged animals was performed 
by a differential PCR based on the recognition of the 9GL and the β-GUS gene in Pret4 
and Pret∆9GL, respectively.  
Thermocycler settings were 95°C for 1 minute, followed by 32 cycles of 95°C for 30 
seconds and 68°C for 1 minute. 
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Detection of a 160-bp fragment of the 9GL gene was performed using the following pair 
of primers:  
Forward: 5’ GTAAGATACGAAAAGGCGTG 3’ 
Reverse: 5’ CATTGGGGACCTAAATAC 3’ 
Detection of a 485-bp fragment of the β-GUS gene was performed using the following 
pair of primers:  
Forward: 5’ GCAATTGCTGTGCCAGGCAGTT 3’ 
Reverse: 5’ TGCCAGTCAACAGACGCGTG 3’ 
Table 2.3 PCR mixture was set up as follows: 
Reagent Volume 
10X Buffer 5 µl 
Water 40 µl 
dNTPs 1 µl 
Taq Polymerase 1 µl 
Forward Primer 100 picomoles/µl 1 µl 
Reverse Primer 100 picomoles/µl 1 µl 
Sample DNA  1 µl 
2.7 Serological assays  
 2.7.1 In-house indirect ELISA 
Antigen preparation and ELISA procedures were based on the methods of (Katz 
et al., 2012) with minor adjustments. Briefly, Vero cells were infected with Vero-adapted 
ASFV Georgia (Krug et al., 2015) and incubated until cytopathic effect reached 100%. 
The infected cells were resuspended in water containing protease inhibitor (Roche), and 
then Tween 80 (G-Biosciences) and sodium deoxycholate (Sigma) were added to a final 
concentration of 1% (v/v) each. Uninfected Vero cells were treated in the same manner 
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and all antigen preparations were stored at -70°C. Maxisorb ELISA plates (Nunc) were 
coated overnight at 4°C with 1 µg per well of either infected cell or uninfected cell 
antigen. Antigen concentration was determined by the Bradford assay. The plates were 
blocked with PBS containing 10% (w/v) skim milk powder (Merck) and 5% (v/v) normal 
goat serum (Sigma) for 2 hours at 37°C. Then plates were washed with PBS 3 times. 
Each serum sample was tested at multiple dilutions (1/10, 1/100, 1/1000, and 1/10,000) 
against both infected and uninfected cell antigen and incubated at 37°C for 1 hour. 
Plates were washed 3 times with PBS. ASFV-specific antibodies in the swine sera were 
detected by an anti-swine IgG-horseradish peroxidase conjugate (KPL) using a 1:1500 
dilution and incubated at 37°C for 1 hour, detected by peroxidase substrate (SureBlue 
Reserve, KPL). Plates were read at a wavelength of 630 nm in an ELx808 plate reader 
(BioTek). Swine sera were considered positive for ASFV-specific antibodies if the OD630 
ratio of the reaction against infected cell antigen to uninfected cell antigen was higher 
than 2.2. The serum dilution was considered negative if the ratio was less than 1.5.  
 2.7.2 Svanovir commercial ELISA 
The Svanovir ASFV-Ab Indirect ELISA kit was used to detect swine antibodies 
against p30 ASFV antigen. Serum samples were diluted 1/100 in sample dilution buffer 
by adding10 µl of serum to 990 µl buffer. Serum was tested against control antigen and 
ASF viral antigen by adding 100 µl of diluted serum to the corresponding wells in 
duplicate. Plates were sealed, gently mixed in a rocker and incubated at 37°C for 1 
hour. Subsequently, plates were rinsed four times with PBS 0.05% Tween buffer. One 
hundred µl of HRP conjugate was added to each well, and again incubated at 37°C for 
1 hour. Plates were rinsed three times with PBS/Tween and 100 µl of substrate solution 
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was added to each well and incubated for 10 minutes at room temperature. The color 
reaction was terminated by adding 50 µl of Stop Solution to each well and mixing 
thoroughly.  
The optical density of each well at 450 nm was measured in a microplate photometer 
(using air as blank). Plates were read at OD450 in an ELx808 plate reader (BioTek). 
Calculations: 
OD ASFV – OD control = OD corrected 
Percent Positivity 
PP = (OD corr. Sample or Negative Control / OD corr. Positive Control) * 100 
Control values should fall within these limits: 
OD Positive Control > or = 0.5 
OD Negative Control < or = 10 
 2.7.3 Immunoperoxidase assay for detecting anti-ASFV antibodies 
Anti-ASFV antibodies in sera of infected animals were quantified with an in-
house immunoperoxidase assay, where Vero cells in 96-well plates were infected (at 
MOI 0.1) with Vero-adapted ASFV Pret4. Infected cell monolayers were fixed in 50% 
acetone and 50% methanol for 10 minutes at room temperature. Plates were blocked 
with 5% (w/v) skim milk powder (Millipore, Billerica, MA) and 0.05% (v/v) Tween 20 
(Sigma, St Louis, MO) for a 1 h at 37°C. Two-fold dilutions (1/501/6400) of the sera 
were diluted in the milk + tween + PBS1X blocking buffer and subsequently incubated 
on the infected cell monolayers in duplicates for 1 h at 37°C. After washing with PBS, 
the presence of anti-ASFV antibodies was detected by using Vector biotinylated goat 
anti-swine IgG (H+L) and the Vectastain ABC HRP kit (Vector Laboratories, CA). Titers 
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were expressed as the inverse log10 of the highest serum dilution with positive 
cytoplasmic staining. A positive control (a serum previously showing strong staining in 
1/6400) and a naïve serum for a negative control were diluted in two fold dilutions and 
added to every plate for quality control. See setup below. 
 
 
 
 
 
 
Figure 2.4 Immunoperoxidase dilution scheme 
 2.8 Peripheral blood mononuclear cell isolation technique and IFN-γ 
ELISpot 
Detection of ASFV-specific IFN-γ producing cells was performed using a 
modification of the ELISpot porcine IFN-γ method by R&D Systems. A monoclonal 
antibody specific for porcine IFN-γ is pre-coated onto polyvinylidene difluoride-backed 
microplates. When the plates are incubated with stimulated PBMCs, this antibody binds 
and immobilizes IFN-γ produced by the cells. Bound IFN-γ is then visualized and 
quantified. 
Fifteen mL of porcine blood were mixed with 20 mL of PBS at room temperature 
in 50-mL conical tubes. Twelve mL of Ficoll Paque Plus at a density of 1.077 g/mL was 
carefully pipetted under the blood/PBS mixture and spun at 420 × g for 32 minutes at 
room temperature with the acceleration and brake set to zero.  
1 2 3 4 5  -    + 
1/50 
1/100 
1/200 
1/400 
1/800 
1/1600 
1/3200 
1/6400 
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The cells were diluted in trypan blue 1/20 and counted manually on a hemocytometer, 
and concentration was adjusted to 5×106/ml. Cells in a volume of 100 µl were placed in 
a round-bottom 96-well plate and then spun at 640 × g for 4 minutes. The supernatant 
was removed carefully without disturbing the cell pellet. One hundred µl of Vero-
adapted Pret4 (2.5×106 per ml; MOI of 0.5), a non-specific cell stimulant (25ng/mL 
phorbol 12-myristate 13-acetate [PMA] and 25ng/mL calcium ionomycin; positive 
control) or sterile media (negative) were added to the cells in triplicates. The mixtures 
were immediately transferred to the ELISpot plate and incubated for 18 hours at 37°C 
with 5% CO2. Cell lysis, washing and detection by anti-IFN-γ antibody, streptavidin-AP 
and BDIP/NBT chromogen were sequentially performed as recommended by the 
manufacturer. Spot counts were performed with an ELISpot plate reader (Immunospot, 
Cellular Technology Limited) with the following settings: counting mask size 100%, 
normalize counts of mask: Off, sensitivity: 130, min. spot size: 0.086 sq.mm, max. spot 
size: 0.2596 sq. mm, oversized spots were estimated at spot separation: 1, diffuseness: 
large, background balance: 67. Cell counts were expressed as a number of spots per 5 
× 105 PBMC. 
 
 
 
 
 
 
Figure 2.5 ELISpot cell count from CTL plate reader 
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 2.7 Cytokine ELISA 
Levels of serum MCP2, TGF-β1, IFN-α, IFN-β, IFN-γ, IL1-α, IL1-β, IL-2, IL-5, IL-
8, IL-10, IL-12 p35, IL-12 p40, OAS, PKR, TNF, MX-1, and VCAM were assessed using 
commercial ELISAs following manufacturer protocols (MyBioSource, San Diego, CA). 
Table 2.4 Cytokines, chemokines, ELISA kits 
 
  Cytokine Kit Manufacturer # 
1 Porcine VCAM-1/CD106 (soluble Vascular Cell Adhesion Molecule 1 MBS2515499 
2 Porcine Total Tumor Necrosis Factor  MBS019118 
3 Porcine 2',5'-Oligoadenylate Synthetase  MBS060350 
4 Porcine Interferon-induced GTP-binding protein Mx1  MBS2601462 
5 Porcine Interleukin 12 p35 MBS754052 
6 Interleukin 6 (IL6)  MBS2021271 
7 Porcine Interferon b, IFN-b MBS9300061 
8 Porcine Monocyte Chemotactic Protein 2 (MCP2)  MBS9308754 
9 Porcine Protein Kinase R MBS058542 
10 TGF-beta1  MBS9302475 
11 Interferon alpha MBS738080 
12 Interleukin 10 MBS761474 
13 Interleukin 12 p 40 MBS268094 
14 Interleukin 5 MBS265447 
15 Interleukin 8 MBS2506194 
16 Interleukin 2 MBS9304562 
17 Interleukin 1 alpha MBS9301200 
18 Interleukin 1 beta MBS01994 
 
 2.8 Immunocytochemistry for ASFV p30 
ASFV antigen was detected in cyrosectioned tissues by using a primary mouse 
monoclonal antibody targeting ASFV p30 (1D9) (Cuesta-Geijo et al., 2012; Galindo et 
al., 2012) (kindly provided by F. Javier Dominguez Juncal, Instituto Nacional de 
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Investigación y Tecnología Agraria y Alimentaria [INIA], Spain) and a commercial 
biotinylated anti-mouse IgG with the VECTASTAIN Avidin Biotinylated Enzyme 
Complex and Vector VIP horseradish peroxidase kits (Vector Laboratories, CA).  
Table 2.5 Reagents for ASFV p30 Detection 
Blocking Buffer (BB) with 
Normal Horse Serum 
ASFV p30 Conjugate Anti-mouse 
IgG 
92 mL MEM 2X Dilute p30 antibody  
1:300  
Dilute anti-mouse IgG 
1:200 or 1 drop per 5 ml 
92 mL Sterile Water Blocking buffer with NHS Blocking buffer with NHS 
10 mL HEPES 1M   
5.3 mL BSA 7.5%   
For every 5mL BB add 1 
drop Normal Horse 
Serum (NHS) 
  
 
Table 2.6 Reagents for ASFV p30 Detection 
A+B Reagent VIP Substrate 
133 µl Bovine Serum 
Albumin (7.5%) 
3 drops Reagent 1 
9.8 mL PBS1X 3 drops Reagent 2 
4 Drops ABC Reagent A 3 drops Reagent 3 
4 Drops ABC Reagent B 3 drops H2O2 
For every 10 mL total For every 5 mL PBS1X 
 
Infected cells on 96-well plates were fixed with 50% acetone and 50% methanol for 10 
minutes at room temperature. Plates were blocked with 100 μl blocking buffer for 20 
minutes at room temperature. Next, 65 μl of diluted anti-ASFV p30 antibody 1D9 were 
added and incubated at room temperature for 30 minutes. A+B Reagent was prepared 
in advance and incubated at room temperature for 30 minutes prior to use. The plates 
were washed 3 times with PBS, 65 µl/well of AB substrate solution was added and 
incubated for approximately 30 minutes at room temperature. AB Reagent was 
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discarded and the plates were washed 3 times with PBS. VIP substrate was made fresh 
in PBS, and 65 μl were pipetted in each well. Plates were incubated for 3-10 min while 
repeatedly checking for developing background straining. To stop the color reaction, the 
VIP substrate was discarded and distilled water was used to wash the plate 3 times. 
 2.9 Immunohistochemistry staining of tissue sections with 1D9 (p30) 
For IHC, OCT-embedded tissue samples were cryosectioned and mounted on 
electrostatically charged glass slides. The slides were fixed in acetone for 10 min at -
20◦C. IHC staining was performed as previously described by (Howey et al., 2013). 
Slides were blocked for 2 h at room temperature with PBS 0.05% Tween (PBST) 
containing 6% (v/v) mixed serum and 2% (w/v) powdered milk. Primary mouse 
monoclonal antibody 1D9, targeting ASFV p30, was diluted 1:300 in PBST and 60 ul 
volume was applied to tissue sections on each slide that were then incubated for 20 h at 
4◦C. For IHC, specific anti-ASFV immunoreactivity was detected using a commercial 
micropolymer alkaline phosphatase detection system (Mach 3 AP; Biocare, CA) as per 
the manufacturer’s recommendation with an alkaline phosphatase substrate (Vector 
Red; Vector Laboratories, CA). Slides were counterstained with Gill’s hematoxylin and 
cover-slipped using routine methods. An adjacent section of each screened tissue was 
treated with a mouse monoclonal antibody against foot-and-mouth-disease virus 
(10GA4) as a negative control. 
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Chapter 3 - Pretoria Swine Experiments 
 3.1 Introduction 
There is no vaccine available against ASF, and the only means of control of ASF 
are strict quarantine and biosecurity measures, control of animal movement, and 
slaughter of exposed and affected herds. Experimental vaccines based on the use of 
inactivated virus or virus subunits have failed to induce solid protective immunity 
(Forman, A. J., 1982; Kihm et al., 1987; Mebus, C., 1988, Chapman et al., 2011, 
Lacasta, A. 2014), but homologous protective immunity does develop in swine surviving 
infections with moderately virulent or attenuated ASFV isolates (Mebus, C., 1988; 
Hamdy and Dardiri, 1984; Ruiz-Gonzalvo et al., 1981). Swine immunized with live 
attenuated ASFVs with genetically engineered deletions of specific virulence-associated 
genes are similarly protected when challenged with homologous parental viruses. 
Previous reports of individual deletions of the UK (DP69R), 23-NL (DP71L), TK (A240L) 
or 9GL (B119L) genes from the genome of virulent ASFV resulted in significant 
attenuation in swine, where swine immunized with these modified viruses demonstrated 
protection when challenged with homologous ASFV (Zsak et al., 1998; Moore et al., 
1998; Lewis et al., 2000; Zsak et al., 1996). These observations are the only 
experimental evidence supporting a rational development of effective live attenuated 
virus against ASFV.  
The deletion of 9GL (B119L) in the highly virulent ASFV isolates Malawi Lil-20/1, 
Pretoriuskop/96/4 (Pret4), and more recently Georgia 2007, resulted in complete 
attenuation of these viruses in swine (Lewis et al., 2000; Neilan et al., 2004; O’Donnell 
et al., 2015a). Therefore, targeting the highly conserved 9GL (B119L) gene for genetic 
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modifications was seen as a reasonable approach for developing attenuated viruses as 
vaccine candidates. Animals infected with Pret4 lacking the 9GL gene (PretΔ9GL) are 
all protected when challenged with Pret4 at 42 days post-infection (dpi) (Neilan et al., 
2004). Challenging Pret4∆9GL-infected animals with the parental virulent Pret4 virus 
earlier than 42 dpi showed a progressive acquisition of protection starting with 40% of 
animals surviving a challenge at 7 dpi and reaching around 80% of protection against a 
challenge between 21 and 28 dpi. Based on these results, we developed an animal 
model to investigate correlates of protection against virulent challenge with Pret4.  
 3.2 Analysis of the Pret4∆9GL genome and the parental Pret4 genome 
To evaluate the status of genetic modification and the integrity of the genome of 
the Pret4∆9GL recombinant virus, full genome sequences of Pret4∆9GL and the 
parental Pret4 viruses were generated using NGS on the Ion Torrent PGM™ and 
compared. From the analysis we found that the Pret4∆9GL virus did not accumulate any 
significant mutations during the process of homologous recombination and sequential 
plaque purification steps. 
 3.2 Analysis of the replication of Pret4 and Pret4∆9GL in vitro  
In vitro growth characteristics of Pret4∆9GL and the parental Pret4 were 
evaluated in primary swine macrophage cell culture and compared in a multistep growth 
curve (Figure 3.1). Pret4∆9GL’s growth was significantly delayed compared to the 
parental Pret4 virus in early time points prior to 96 hours. The 9GL-gene-deleted virus 
exhibited titers 10 to 1000-fold lower relative to the parental virus. The deletion of the 
9GL gene significantly affected the ability of the Pret4∆9GL virus to replicate in vitro in 
primary swine macrophage culture. 
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Figure 3.1 In vitro growth characteristics of Pret4∆9GL (triangles) and parental 
Pret4 (squares). Primary swine macrophage cell cultures were infected with either 
Pret4∆9GL or Pret4 at MOI 0.01 and the virus yield was titrated at different times 
post-infection. Data represents mean and standard deviation (SD) from three 
independent experiments as described in Chapter 2.4. The limit of detection was 
Log10 1.5 HAD50/mL. 
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 3.3 Experimental design and results of comparative pathogenesis 
experiment 
 
Figure 3.2 Experimental Design of comparative pathogenesis study between the 
virulent Pret4 and its attenuated derivative Pret4∆9GL1 
To investigate growth characteristics in vivo, twenty 33-36 kg pigs were 
inoculated intramuscularly with 104 50% hemadsorption doses (HAD50) of virulent Pret4 
or Pret4Δ9GL. Animals were observed daily for fever and clinical signs (see Table 6 
below). Blood samples and nasal swabs were collected every other day for 10 days 
post-infection (DPI). Two animals from each group (n=10) were euthanized and 
necropsied on 2, 4, 6, 8, and 10 days post-infection. Whole blood, nasal swabs, and 
tissue homogenates were titrated on primary peripheral-blood macrophages as 
                                                 
1 Pig clip art is in the public domain. Downloaded from http://cliparts.co/clipart/2303191. 
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previously described (Zsak et al., 2005). Presence of virus was detected by 
hemadsorption and virus titers were calculated by the method of Reed and Muench 
(Reed and Muench, 1938)  
 3.3.1 Comparative pathogenesis between the virulent Pret4 and its 
attenuated derivative Pret4Δ9GL 
 3.3.1.1 Clinical signs 
To assess virus replication in vivo, swine were inoculated with either Pret4∆9GL 
or parental Pret4. Swine were observed daily for fever and ASFV-related clinical signs 
(see Table 2 in Chapter 2.4.1). Swine infected with Pret4 presented with increased body 
temperature of greater than 40°C by 3 to 4 days post-infection. Clinical signs associated 
with ASF became apparent as early as four days post-infection. As ASF progressed, 
swine either died or were humanely euthanized in 6 to 10 days post-infection. Swine 
inoculated with Pret4∆9GL remained clinically normal during the 10-day observational 
period (Fig 3.4). Swine inoculated with Pret4Δ9GL did not have detectable clinical signs 
such as skin hemorrhages, neurologic signs, melena, or pyrexia. 
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Figure 3.3 Comparative pathogenesis in twenty swine: Rectal temperatures (lines) 
and clinical scores (bars) of Pret4 (red squares and pink) bars and Pret4∆9GL 
(blue triangles) infected swine. See clinical scoring in table 2.2 
 3.3.1.2 Viremia and nasal shedding 
Blood samples and nasal swabs were collected every other day for 10 days from 
each group (n=10). Whole blood and nasal swabs were titrated on primary swine 
macrophage cell cultures. Viremia in animals inoculated with Pret4∆9GL peaked 
transiently by day 4 post-infection and remained at significantly lower levels compared 
to swine inoculated with Pret4. The limit of detection was Log10 1.5 HAD50/mL. Swine 
inoculated with Pret4Δ9GL had significantly lower viremia than those inoculated with 
Pret4. No Pret4Δ9GL was detected in nasal swabs. Clinical signs of ASF progressed in 
Pret4-infected swine, nasal shedding of virus was detected as early as 4 dpi. No nasal 
viral shedding was detected by virus isolation in Pret4∆9GL-infected animals. 
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Figure 3.4 Comparative pathogenesis in twenty swine: Virus titers in nasal swabs 
(blue triangles Pret4∆9GL and red boxes Pret4) and blood samples (light blue 
bars Pret4∆9GL and pink bars Pret4). Limit of detection was Log10 1.5 HAD50/mL. 
 3.3.1.3 Virus detection in tissues by virus isolation and 
immunohistochemistry 
The same group of swine that were inoculated with 104 HAD50 of either Pret4 or 
Pret4∆9GL were humanely euthanized (2 swine per time point) from each group at 2, 4, 
6, 8, and 10 days post-inoculation. Ten tissues were collected for virus isolation (Fig 
3.5) and in OCT medium for IHC (3.6) for further characterization of viral antigen 
present in tissues. The 10 tissues collected from each pig included the lingual tonsil, 
palatine tonsil, nasopharyngeal tonsil, epithelium of the dorsal nasal pharynx, lung, a 
submandibular lymph node, liver, spleen, gastrohepatic lymph node, and superficial 
cervical lymph node. The highest Pret4 titers were observed in the spleen, liver, and 
gastrohepatic lymph node. Pret4Δ9GL was found only in spleen at days 2, 4, 6, and 10 
dpi, where as virus was isolated from liver at 4, 6, and 10 dpi. Lastly, Pret4∆9GL virus 
was detected the lung of one pig at 6 dpi. The limit of detection was Log10 1.5 
HAD50/mL.  
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Figure 3.5 Comparative Pathogenesis in 20 swine: Virus titers of tissue macerates 
collected from 2 swine per time point at 2, 4, 6, 8, and 10 days post-inoculation. 
Bars with dark colors set to the back represent an average titer from each tissue 
macerate from two individual animals inoculated with Pret4 at each time point. 
Light pastel colored bars set in the front represent an average titer from each 
tissue macerate from two individual animals inoculated with Pret4∆9GL. Virus 
titer limit of detection: ≤ Log10 1.5 HAD50/mL of tissue macerate.  
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Figure 3.6 Immunohistochemistry staining of frozen spleen section with anti-
ASFV-p30 and hematoxylin at 4 days post-infection with Pret4 (A) and Pret4∆9GL 
(B) 10X magnification. 
 3.3.1.4 Descriptions of IHC from frozen spleen sections 
Spleen from swine infected with Pret4 stained positive extensively for p30 at time 
points between 4 and 10 dpi. The p30 antigen was not detected in any swine infected 
with Pret4∆9GL despite the successful isolation of virus via macrophage culture. IHC 
was only run on spleen samples since the highest titers of Pret4∆9GL were found in the 
spleen. Further IHC of other Pret4∆9GL tissues was not pursued after multiple sections 
had been cut and multiple staining attempts to detect Pret∆9GL in the spleen had been 
made with no result. 
 
 
 
 
A B 
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Figure 3.7 Immunohistochemistry staining of frozen spleen section with anti-
ASFV-p30 and hematoxylin at 4 (top) and 6 days post-infection (bottom) with 
Pret4. Taken at 4X (left) and 20X (right). 
 
These images above in Fig 3.7 show the extensive staining of anti-ASFV p30 
throughout the spleen in swine infected at four and six days post-infection with Pret4. 
ASFV antigen is found within and surrounding the white pulp and red pulp. 
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Figure 3.8 Immunohistochemistry staining of frozen spleen section with anti-
ASFV-p30 and hematoxylin. Spleen from swine infected with Pret4 at 8 (top) and 
10 dpi (bottom) at 4X (left) and 20X (right). 
 
The images in Fig 3.8 above show the extensive staining of anti-ASFV p30 
throughout the spleen of swine infected with Pret4 at 4 and 6 days post-infection. ASFV 
is found within and surrounding the white pulp and red pulp. In pig 734, the lack of 
purple staining indicates severe depletion of lymphocytes throughout the spleen. 
Lymphoid depletion was also visible in pig 730 from 10 dpi but not to the same degree. 
Which organs were most severely affected varied among infected swine. 
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Figure 3.9 Immunohistochemistry staining of a frozen spleen section with anti-
ASFV-p30 and hematoxylin. Spleen from swine infected with Pret4∆9GL at 4 (top) 
and 8 dpi (bottom) at 4X (left) and 20X (right). 
 
These images in Fig 3.9 above representing swine infected with Pret4∆9GL at 4 
and 8 days post-infection are negative for anti-ASFV p30. White spaces in the section 
are an artifact of the sectioning technique. 
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 3.4 Experimental design of onset of protective immunity in 
Pr4Δ9GLv-inoculated animals 
Swine infected with Pret4∆9GL virus were all protected against challenge with 
the parental virulent Pret4 virus at 42 days post-inoculation in an experiment done 
previously by (Neilan et al., 2004). We sought to understand the mechanisms mediating 
protection against ASF at different time points. Using swine weighing 36-55 kg, 
protection was assessed in Pret4Δ9GL-inoculated animals challenged 7, 10, 14, 21, or 
28 days later with 104 HAD50 of Pret4. A group of 15 naïve swine were only challenged 
with Pret4. In each Pret4Δ9GL-inoculated group, animals were challenged at 7, 10, 14, 
21, and 28 DPI with Pret4. Sample size was n=15 for the 7-day challenge group, n=10 
for the 10-day challenge group, n=15 for the 14-day challenge group, n=10 for the 21-
day challenge group, and n=15 for those challenged at day 28. All swine were bled at 4, 
7, 11, 14, 21, 28 days post-inoculation (DPI), and 4, 7, 11, 14, and 21 days post-
challenge (DPC) unless otherwise noted. Whole blood samples were titrated on primary 
swine peripheral blood mononuclear cells. 
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 3.4.1 Naïve swine controls challenged with Pret4 
 
Figure 3.10 Twenty naive swine served as controls, groups of 5 swine were 
challenged with Pret4 in four separate experiments. None of the animals survived. 
Non-survivors are marked with a red ‘X’.2 
 
Twenty swine were used in four separate experiments, with five animals in each 
group. All swine were challenged with 1 mL of 104 Pret4 HAD50 intramuscularly. All 
swine in the control group died or were humanely euthanized between 5 and 15 days 
post-challenge. 
 
 
 
  
                                                 
2 Pig clip art is from http://www.clker.com/clipart-29067.html 
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3.4.2 Swine inoculated with Pret4∆9GL and subsequently challenged 7 days 
post-inoculation with Pret4 
 
Figure 3.11 Fifteen swine in 3 groups of 5 were inoculated with Pret4Δ9GL and 
challenged with Pret4 7 days later. Swine were observed for 21 days following 
challenge. Non-survivors are marked with a red ‘X’. 
Fifteen swine were used in three separate experiments, with five animals in each 
group. All swine were inoculated with 104 HAD50 Pret4∆9GL and challenged seven days 
later with 104 HAD50 Pret4. Nine swine or 60% in the 10-day group died or were 
humanely euthanized between 9 and 12 days post-challenge. 
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 3.4.3 Swine inoculated with Pret4∆9GL and subsequently challenged 10 
days post-inoculation with Pret4 
 
Figure 3.12 Ten swine in 2 groups of 5 were inoculated with Pret4Δ9GL and 
challenged with Pret4 10 days later. Swine were observed for 21 days following 
challenge. Non-survivors are marked with a red ‘X’.  
Ten swine were used in two separate experiments, with five animals in each 
group. All swine were inoculated with 104 HAD50 Pret4∆9GL and challenged ten days 
later with 104 HAD50 Pret4. Four swine or 40% in the 10-day group died or were 
humanely euthanized between 6 and 9 days post-challenge. 
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 3.4.4 Swine inoculated with Pret4∆9GL and subsequently challenged 14 
days post-inoculation with Pret4 
 
Figure 3.13 Fifteen swine in 3 groups of 5 were inoculated with Pret4Δ9GL and 
challenged with Pret4 14 days later. Swine were observed for 21 days following 
challenge. Non-survivors are marked with a red ‘X’.   
Fifteen swine were used in three separate experiments, with five animals in each 
group. All swine were inoculated with 104 HAD50 Pret4∆9GL and challenged ten days 
later with 104 HAD50 Pret4. Four swine or 27% in the 14-day group died or were 
humanely euthanized between 8 and 18 days post-challenge. 
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 3.4.5 Swine inoculated with Pret4∆9GL and subsequently challenged 21 
days post-inoculation with Pret4 
 
Figure 3.14 Ten swine in 2 groups of 5 were inoculated with Pret4Δ9GL and 
challenged with Pret4 21 days later. Swine were observed for 21 days following 
challenge. Non-survivors are marked with a red ‘X’.   
Ten swine were used in two separate experiments, with five animals in each 
group. All swine were inoculated with 104 HAD50 Pret4∆9GL and challenged ten days 
later with 104 HAD50 Pret4. Two swine or 20% in the 21-day group died or were 
humanely euthanized between 11 and 14 days post-challenge. 
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 3.4.6 Swine inoculated with Pret4∆9GL and subsequently challenged 28 
days post-inoculation with Pret4 
 
Figure 3.15 Fifteen swine in 3 groups of 5 were inoculated with Pret4Δ9GL and 
challenged with Pret4 28 days later. Swine were observed for 21 days following 
challenge. Non-survivors are marked with a red ‘X’.   
 
Fifteen swine were used in three separate experiments, with 4, 5, and 6 animals 
in each group. All swine were inoculated with 104 HAD50 Pret4∆9GL and challenged 10 
days later with 104 HAD50 Pret4. Three swine or 20% in the 28-day group died or were 
humanely euthanized between 6 and 11 days post-challenge. 
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 3.5 Results of onset of protective immunity in Pr4Δ9GLv-inoculated 
animals 
 3.5.1 Assessment of survival status of swine in individual challenge 
groups 
Swine infected with Pret4∆9GL are all protected when challenged with Pret4 at 
42 days post-infection (Neilan et al., 2004). Challenging Pret4∆9GL infected animals 
with the parental virus Pret4 showed a progressive acquisition of protection starting with 
40% of the challenged animals at 7 dpi and reaching 80% surviving between 21 and 28 
dpi. 
 
Figure 3.16 Percentage of surviving animals after challenge with Pret4 at different 
times post-inoculation with Pret4∆9GL.  
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Swine were inoculated with 104 HAD50/mL Pret4∆9GL virus and challenged with 
virulent Pret4 via the same dose and route at either 7 (n=15), 10 (n=10), 14 (n=15), 21 
(n=10), or 28 (n=15) days later and clinically observed for 21 days post-challenge (see 
Fig 3.16). In our study, 6 out of 15 (40%) animals challenged as early as 7 days post-
inoculation with Pret4∆9GL survived the challenge. When swine inoculated with 
Pret4∆9GL virus were challenged at later time points, an increase in the portion of 
animals surviving the virulent challenge occurred. Six out of 10 (60%), 11 out of 15 
(73%), 8 out of 10 (80%), and 12 out of 15 (80%) swine survived when challenged at 
10, 14, 21, and 28 days post-inoculation with Pret4∆9GL. 
 3.5.2 Clinical signs and rectal temperatures 
Swine surviving challenge presented with transient pyrexia at times (see 
Appendix A Fig 5.1-5.7), typically around 1-6 days post-challenge. On average all 
surviving swine in the different challenge groups remained at temperatures below 40°C, 
with the exception of swine in the 14-day challenge group, where many surviving swine 
had elevated temperatures following challenge in the first week (see Fig 3.17- 3.22). 
These swine appeared to be generally healthy as they were active and eating. 
Non-survivors had a mostly consistent presentation of clinical signs associated 
with ASF. Fever, lack of appetite, inability to stand, and staggered gait were observed in 
all non-protected swine. It appears that the clinical presentation of the disease did not 
differ between animals challenged at early or later times.   
 3.5.3 Viremia of swine in the different challenge groups 
The surviving swine presented with a broad range of viremia titers from 103 
HAD50/mL to 108 HAD50/mL. Many of the swine that succumbed to the virulent challenge 
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had temperatures, viremia kinetics, and clinical signs similar to naïve challenged swine 
by 3-5 days post-challenge, with euthanasia or death mainly occurring at 8-11 days 
post-challenge. 
 3.5.3.1 Viremia and rectal temperatures of naïve control swine challenged 
with Pret4 
 
Figure 3.17 Average rectal temperature (black) and viremia titer (orange) of naïve 
control swine infected with Pret4. Filled circles represent mean values for non-
survivors. Data represents mean values, error bars are standard deviation (SD) 
from 20 individual animals. Limit of detection: Log10 1.5 HAD50/ml. 
 
Naïve control swine all developed clinical signs of ASF, including fever, loss of 
appetite, staggering gait, petechial hemorrhage, melena, and cyanosis of ears. Viremia 
was detected as early as 4 days post-inoculation in most swine. Fever was observed as 
early at 3-4 days post-challenge.  
 3.5.3.2 Viremia and rectal temperatures of survivors and non-survivors 
inoculated with Pret4∆9GL and challenged 7 days post-inoculation 
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Figure 3.18 Average rectal temperature (purple) and viremia titers (orange) of 7-
day challenge swine. Filled circles represent mean values for non-survivors, 
while open circles are mean values for survivors. The chart shows means and SD 
from 15 individual animals, with 6 survivors and 9 non-survivors. Limit of 
detection: Log10 1.5 HAD50/mL. 
 
All non-survivors in the 7-day challenge group had clinical signs of ASF and 
viremia that were indistinguishable from naïve control animals. Surviving swine had 
viremia and temperatures that, on average, were much lower than non-survivors. This 
divergence was visible within a few days following challenge. Interestingly, the onset of 
fever was on average at 11 days post-challenge. Observing temperatures of animals 
individually, it was apparent that 2 out of 6 surviving swine had transient temperature 
peaks above 40°C with an average duration of almost 2 days (see Fig A.5.3 and Table 
3.1). These two animals also had transient peaks of viremia greater than 103 HAD50/mL.  
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 3.5.3.3 Viremia and rectal temperatures of survivors and non-survivors 
inoculated with Pret4∆9GL and challenged 10 days post-inoculation 
 
Figure 3.19 Average rectal temperature (green) and viremia titers (orange) of 
swine inoculated with Pret4∆9GL and subsequently challenged with Pret4 10 days 
later. Filled circles represent and mean values for non-survivors, while open 
circles are mean values for survivors. The chart shows means and SD with 5 
survivors and 4 non-survivors Limit of detection: Log10 1.5 HAD50/mL. 
All non-survivors in the 10-day challenge group had clinical signs of ASF 
indistinguishable from naïve control animals. In the swine surviving the challenge, half 
did not have viremia peaking higher than 106 HAD50/ml, or temperatures peaking above 
40°C (Fig A.5.4). By 21 days, viremia decreased to 103 HAD50/mL in four out of the six 
survivors. Non-surviving swine had higher viremia titers reaching above 106 HAD50/mL 
within 7 days post-challenge and rectal temperatures were also elevated to above 41°C 
following challenge.  
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 3.5.3.4 Viremia and rectal temperatures of survivors and non-survivors 
inoculated with Pret4∆9GL and challenged 14 days post-inoculation 
 
Figure 3.20 Average rectal temperatures (turquoise) and viremia titers (orange) of 
swine inoculated with Pret4∆9GL and challenged at 14 days post-inoculation. 
Filled circles represent and mean values for non-survivors, while open circles are 
mean values for survivors. The chart shows means and standard deviation (SD) 
from 15 individual animals, with 11 survivors and 4 non-survivors. The limit of 
detection was Log10 1.5 HAD50/mL. 
Differences between non-surviving and surviving swine were less apparent, with 
the exception of the rising temperatures of non-survivors around 10 days post-
challenge. At least eight out of eleven survivors had viremia peaking above 106 
HAD50/mL post-challenge, with all but 2 swine presenting with transient temperatures 
above 40°C (Fig A.5.5). These transient peaks in temperatures lasted longer in the 14-
day challenge group, on average 6.2 days (see Table 3.1). All non-survivors had clinical 
signs of ASF, temperatures, and viremia levels indistinguishable from the naïve control 
animals.  
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 3.5.3.5 Viremia and rectal temperatures of survivors and non-survivors 
inoculated with Pret4∆9GL and challenged 21 days post-inoculation 
 
Figure 3.21 Average rectal temperature (red) and viremia titers (orange) of swine 
inoculated with Pret4∆9GL and subsequently challenged with Pret4 21 days later. 
Filled circles represent and mean values for non-survivors, while open circles are 
mean values for survivors. The chart shows means and SD from 10 individual 
animals, with 8 survivors and 2 non-survivors. The limit of detection was Log10 
1.5 HAD50/mL. 
There is a clear divergence between the groups of survivors and non-survivors. 
Of the survivors, half had viremia titers peak above 106 HAD50/ml, and a majority of 
these animals also had a short peak in temperatures above 40°C, on average lasting 
about 2 days (see Fig A.5.6 and Table 3.1). The 2 non-survivors had sharp increases in 
viremia, followed by clinical signs of ASF indistinguishable from naïve control animals.  
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 3.5.3.6 Viremia and rectal temperatures of survivors and non-survivors 
inoculated with Pret4∆9GL and challenged 28 days post-inoculation 
 
Figure 3.22 Average rectal temperature (blue) and viremia titers (orange) of 
Pret4∆9GL swine challenged 28-days post-inoculations with Pret4. Filled circles 
represent and mean values for non-survivors, while open circles are mean values 
for survivors. This chart shows the means and SD from 15 individual animals, 
with 12 survivors and 3 non-survivors. The limit of detection was Log10 1.5 
HAD50/mL. 
All non-survivors had clinical signs of ASF indistinguishable from naïve control 
animals. Only 2 out of 10 swine surviving the challenge had viremia greater than 106 
HAD50/mL prior to challenge, while most viremia titers were at 103 HAD50/mL or 
undetectable by 21 days post-challenge (See Fig A.5.7). On average fever began 11 
days post-challenge and lasted for almost 4 days in the 12 survivors. 
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 3.5.3.7 Summarizing viremia post-challenge of survivors and non-
survivors previously inoculated with Pret4∆9GL  
 
 
Figure 3.23 Summary of viremia in animals challenged with Pret4 virus at different 
times after inoculation with Pret4∆9GL. Black filled shapes represent animals that 
did not survive; white open shapes represent animals that survived challenge.  
In Fig 3.23 the contrast between the viremia in surviving and non-surviving 
animals is apparent. Among the groups we also see that the 28-, 7-, and 21-day 
challenge groups have the lowest viremia among surviving swine. The 14-day challenge 
group had the highest viremia among surviving animals. Non-surviving swine are 
indistinguishable between groups.  
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 3.5.3.7 Summarizing rectal temperatures post-challenge of survivors and 
non-survivors previously inoculated with Pret4∆9GL  
 
Figure 3.24 Summary of temperatures in animals challenged with Pret4 virus at 
different times after inoculation with Pret4∆9GL. Black filled shapes represent 
animals that did not survive; white open shapes represent animals that survived 
challenge. The mean and SD of each group were shown in the previous figures. 
Among the average temperatures, stark differences are clear between swine that 
survived challenge and swine that did not. In general, we observe that surviving swine 
in the 21- and 7-day challenge groups had the lowest temperatures on average. 
 
 
 
 
 
 96 
 3.5.4 Virus typing by PCR post-challenge for swine previously inoculated 
with Pret4∆9GL 
 
Figure 3.25 PCR detection of Pret4∆9GL and Pret4 virus DNA using specific 
primers. (A) Assessment of the presence of β-GUS genes to detect Pret4∆9GL. 
The first band is a plasmid containing β-GUS, the second band is the Pret∆9GL 
Virus, the third band is parental Pretoria stock virus, and fourth is the water 
control. (B) Assessment of the presence of 9GL gene to detect parental Pret4. The 
first band is a plasmid containing β-GUS, the second band is the Pret∆9GL Virus, 
the third band is parental Pretoria stock virus, and fourth is the water control.  
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Figure 3.26 Virus detection by PCR, determining the presence of the 9GL (B119L) 
or β-GUS genes. Blue boxes represent positive result for Pret4∆9GL virus, red 
boxes represent positive results for the parental Pret4 virus, and black boxes 
indicate that the PCR was positive for both viruses. 
Figure 3.27 illustrates the characterization of circulating virus after the challenge 
of swine inoculated with Pret4∆9GL. Only the blood sample with the highest viremia titer 
was tested from each animal. Sample time points ranged from 4 to 14 days following 
challenge. Specific detection of Pret4 and/or Pret4∆9GL was performed by differential 
PCR based on the detection of the 9GL (B119L) or β-GUS genes. 
In general, there was a heterogeneous distribution of finding both or either one of 
the viruses in all groups, with the exception of the 21-day challenge group where Pret4 
was never found by itself. 
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 3.5.5 Analysis of immune responses and viremia in swine infected with 
Pret4∆9GL at the time of challenge 
 3.5.5.1 Viremia at the time of challenge 
An infection with Pret4∆9GL may be a competitive factor in the process of 
protection against the challenge with virulent Pret4 virus. We looked for a correlation 
between survival and the presence of Pret4∆9GL viremia at the time of challenge at 
7,10, 14, 21, and 28 days post-inoculation with Pret4∆9GL. In general, it was found that 
the viremia levels varied from pig to pig independent of the time post-challenge and 
independent of their survival following challenge. Swine surviving challenge had viremia 
titers ranging from as low as undetectable (<1.5 log10 HAD50/ml) to values peaking at 4-
7 log10 HAD50/mL. Consequently, detection of viremia at a particular level was not 
associated with protection against a virulent challenge with Pret4. 
 3.5.5.2 Detection of anti-ASFV antibody at the time of challenge 
We focused on antibody levels at the time of challenge in Pret4∆9GL-inoculated 
swine using two different in-house developed assays, indirect ELISA and an 
immunoperoxidase assay (IPA). In all 15 swine challenged at 7 dpi, antibodies were 
undetectable by ELISA independent of survival status (Fig. 3.27) We detected antibody 
in only 2 of the 6 surviving swine at 10 days post-inoculation by ELISA, while 4 of the 6 
survivors were detected by IPA (Fig 3.28). Comparably, in 11 swine surviving challenge 
at 14 days post-inoculation, 4 were positive by ELISA, and 8 were positive by IPA (Fig 
3.29). Consequently the detection of antibody by ELISA or IPA did not correlate with 
swine surviving challenge.  
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Analyzing the detection of antibody titers in swine challenged at later times 
seemed to indicate an association with survival. The antibody detected by either IPA or 
ELISA were lower or absent in swine challenged at 21 days post-inoculation that did not 
survive (Fig 3.30). Evidently, in the group of swine challenged at 28 days post-
inoculation with Pret4∆9GL, all surviving swine had detectable antibody by both ELISA 
and IPA (Fig 3.31). The 3 swine that did not survive the challenge in this group did not 
have detectable antibody.  
 3.5.5.2 Detection of IFN-γ in ASFV-stimulated PBMCs at the time of 
challenge 
PBMCs from swine were stimulated with Vero-adapted Pret4 to measure IFN-γ 
responses by ELISPOT. We focused on the IFN-γ at the time of challenge for each 
group to investigate any T-cell sensitization to ASFV. We found no significant 
differences in the number of IFN-γ-producing PBMCs on the day of challenge between 
swine surviving challenge and those that did not, independent of the time of challenge 
(See Fig 3.21 to 3.31 for IFN-γ measurements on the day of challenge). Results of the 
IFN-γ ELISA for more time points can be found in Appendix A.  
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Figure 3.27 Viremia and immune parameters 7 days after infection with 
Pret4Δ9GL (day of challenge with parental Pret4). Log10 values of viremia, anti-
ASFV antibody titer detected by ELISA and immunoperoxidase (IPA), and the 
number of circulating ASFV-specific IFN-γ-producing PBMCs are represented for 
each individual pig. Survival status of swine is indicated as “survived” (white 
open shapes), or “did not survive” (black filled shapes). Virus titer limit of 
detection: ≤ Log10 1.5 HAD50/mL. ELISA limit of detection:≤ Log10(1/10). IPA limit of 
detection:≤ Log10(1/200).  
No antibody was detected by ELISA at 7 days post-inoculation with Pret4∆9GL 
(see Fig 3.27). The IPA assay detected antibody in 6 of 15 swine 7 days after 
inoculation. Of the animals with detectable antibody, 3 out of 6 survived the challenge. 
The presence of IFN-γ production in PBMCs did not differ between survivors and non-
survivors. Viremia on the day of challenge (7 dpi) varied in all swine and had no bearing 
on survival status. 
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Figure 3.28 Viremia and immune parameters 10 days after infection with 
Pret4Δ9GL (day of challenge with parental Pret4). Log10 values of viremia, anti-
ASFV antibody titer detected by ELISA and IPA, and the number of circulating 
ASFV-specific IFN-γ-producing PBMCs are represented for each individual pig. 
Survival status of swine is indicated as “survived” (white open shapes), or “did 
not survive” (black filled shapes). Virus titer limit of detection: ≤ Log10 1.5 
HAD50/mL. ELISA limit of detection:≤ Log10(1/10). IPA limit of detection:≤ 
Log10(1/200).  
The ELISA assay detected antibodies in 3 of 10 pigs, while IPA detected 
antibodies in 6 of these animals (see Fig 3.28). Of the swine that survived, 4 out of 6 
had antibody detectable by IPA and 2 were also positive by ELISA. The presence of 
IFN-γ production in PBMCs did not differ between survivors and non-survivors. 
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Figure 3.29 Viremia and immune parameters 14 days after infection with 
Pret4Δ9GL (day of challenge with parental Pret4). Log10 values of viremia, anti-
ASFV antibody titer detected by ELISA and IPA, and the number of circulating 
ASFV-specific IFN-γ-producing PBMCs are represented for each individual pig. 
Survival status of swine is indicated as “survived” (white open shapes), or “did 
not survive” (black filled shapes). Virus titer limit of detection: ≤ Log10 1.5 
HAD50/mL. ELISA limit of detection:≤ Log10(1/10). IPA limit of detection:≤ 
Log10(1/200).  
Antibodies were detected in 6 out of 15 animals by ELISA and in 11 out of 15 by 
IPA. Of the 11 swine that survived the challenge, 4 were positive by ELISA, and 8 were 
positive by IPA. The presence of IFN-γ production in PBMCs did not differ between 
survivors and non-survivors, nor did the detection of viremia. 
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Figure 3.30 Viremia and immune parameters 21 days after infection with 
Pret4Δ9GL (day of challenge with parental Pret4). Log10 values of viremia, anti-
ASFV antibody titer detected by ELISA and IPA, and the number of circulating 
ASFV-specific IFN-γ-producing PBMCs are represented for each individual pig. 
Survival status of swine is indicated as “survived” (white open shapes), or “did 
not survive” (black filled shapes). Virus titer limit of detection: ≤ Log10 1.5 
HAD50/mL. ELISA limit of detection:≤ Log10(1/10). IPA limit of detection:≤ 
Log10(1/200).  
Antibody was detected in all 8 survivors by ELISA and IPA. The two non-
survivors had low or undetectable antibody by IPA and ELISA. IFN-γ was only tested in 
the second experiment in which all swine survived. 
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Figure 3.31 Viremia and immune parameters 28 days after infection with 
Pret4Δ9GL (day of challenge with parental Pret4). Log10 values of viremia, anti-
ASFV antibody titer detected by ELISA and IPA, and the number of circulating 
ASFV-specific IFN-γ-producing PBMCs are represented for each individual pig. 
Survival status of swine is indicated as “survived” (white open shapes), or “did 
not survive” (black filled shapes). Virus titer limit of detection: ≤ Log10 1.5 
HAD50/mL. ELISA limit of detection:≤ Log10(1/10). IPA limit of detection:≤ 
Log10(1/200).  
Antibody was detected in all 12 survivors by ELISA and IPA. The 3 non-survivors 
had low or undetectable antibody by ELISA and IPA. IFN-γ detected in stimulated 
PBMCs was higher in all 8 surviving swine that were tested. The IFN-γ ELISPOT assay 
was not used in the first experiment.  
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Figure 3.32 Evaluation of systemic levels of different host cytokines in swine 
inoculated with Pret4∆9GL virus. Average values and 95% confidence intervals of 
15, 10, and 15 animals are shown for the groups challenged at 7, 10, 14 days post-
inoculation with Pret4∆9GL. All values are expressed as a concentration per mL 
of serum. Survival status of swine is indicated as “survived” (white open shapes), 
or “did not survive” (black filled shapes).  
No specific or unique patterns of cytokine levels in serum were observed in swine 
that did or did not survive challenge. 
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Table 3.1 Summary of Pretoria swine studies 
Group 
No. of 
Surviving 
% 
Fever 
Mean days 
until fever 
(±SD) 
Mean 
duration of 
fever in 
days (±SD) 
Max 
Temp 
°C 
Mean days 
until death 
(±SD) 
Control 0/20 100 4.1±1.0 4.4±1.7 41.6 8.3±3.2 
7-day 
challenge 
6/15 
 
S: 33 11.0±2.8 1.5±0.7 40.7  
N:100 3.7±1.4 6.0±2.1 41.8 9.3±1.1 
10-day 
challenge 
6/10 
S: 50 6.0±2.7 2.7±1.2 40.7  
N:100 3.0±0.8 4.8±1.5 41.7 7.3±1.6 
14-day 
challenge 
11/15 
S: 64 5.4±2.9 6.2±4.3 41.3  
N:100 6.0±3.4 6.0±2.6 41.4 13.0±5.0 
21-day 
challenge 
8/10 
S:25 9.2±6.7 2.0±1.4 40.7  
N:100 3.0±0.0 8.5±2.1 41.3 12.5±1.5 
28-day 
challenge 
12/15 
S: 50 11.0±7.7 3.8±1.2 41.1  
N:100 7.0±6.1 
6.0±2.6 
 
41.2 9.0±2.6 
S: Swine surviving challenge with Pret4 
N: Swine that did not survive challenge with Pret4 
 
This table summarizes all Pretoria swine experiments conducted to determine 
the time of onset of protective immunity. In general, fever in non-survivors began around 
3 days post-challenge, whereas surviving swine had fever from around 5 to 11 days 
post-challenge. Between 25% and 64% of surviving challenge presented with fever. 
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Chapter 4 - Georgia Swine Experiments 
 4.1 Introduction 
The epidemic ASFV strain Georgia 2007/1 is a highly virulent virus that entered 
the Caucasus region in early 2007 and since then has spread to Armenia, Azerbaijan, 
and Russia. Further outbreaks have also been reported in Ukraine, Belarus, Lithuania, 
Latvia, and Poland, ultimately posing a risk to the whole of Europe. Developing a 
vaccine against the Georgia isolate is critical. To further extend our knowledge and 
cross-validate our results, the vaccination/challenge model used in the Pretoria 
experiments was also utilized with a double-deletion mutant of Georgia 2007, 
Geo∆9GL/∆UK, and its parental strain.  
In order to attenuate Georgia 2007, our lab deleted two genes: 9GL (B119L) and 
UK (DP96R). The double mutant containing these two deletions was completely 
attenuated in swine. It was found that swine inoculated with Geo∆9GL/∆UK and 
challenged with parental Georgia 2007 at 28 days post-inoculation had 100% survival. 
To determine the appropriate vaccination regimen, we tested doses of 102, 104, 
and 106 HAD50 and assessed antibody levels as well as IFN-γ production in stimulated 
PBMCs for all animals at the time of challenge. We found that 104 HAD50 was a 
sufficient vaccine dose. All swine inoculated with that dose were clinically normal for the 
28-day observational period and all survived challenge with virulent Georgia at 28 dpi. 
With this model, we also investigated immune factors (antibody, IFN-γ in PBMCs, 
and 18 serum cytokines) associated with protection against virulent challenge as early 
as 7 to 14 days post-inoculation and later at 21 and 28 days post-inoculation and 
compared the results to those observed with the Pret4Δ9GL model. 
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 4.2 Experimental design of Geo∆9GL/∆UK dose-response study in 
swine 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Dose-response study of Geo∆9GL/∆UK and subsequent challenge at 28 
days with 103 HAD50 Georgia 2007. Swine marked with a red X did not survive 
challenge. 
Swine were inoculated with 102, 104, or 106 HAD50 of Geo∆9GL/∆UK and 
subsequently challenged with virulent Georgia 2007 28 days later to find an appropriate 
vaccine dose. Experiments were conducted in groups of 4 or 5 pigs. Swine receiving 
102 HAD50 had 44% survival (4/9), compared to 100% (10/10) for 104 HAD50 and 93% 
(14/15) for 106 HAD50. Control animals showed ASF-related signs as early as 3 days 
post-infection with a majority of them being euthanized at 5 or 6 days post-challenge. 
 
106 HAD50 28 Day Challenge 
Naive 
Challenge 
102 HAD50 28 Day Challenge 104 HAD50 28 Day Challenge 
Naive 
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 4.2 Experimental design of Geo∆9GL/∆UK onset of protective 
immunity in swine 
 
 
 
 
 
Figure 4.2 Analysis of the onset of protection for inoculation with 104 HAD50 of 
Geo∆9GL/∆UK and subsequent challenge at 7, 14, 21 days with 103 HAD50 of 
Georgia 2007. Swine marked with a red X did not survive challenge. 
 
Of the 5 swine challenged 7 days post-inoculation with Geo∆9GL/∆UK, one 
survived the challenge. When challenged at 14 days post-inoculation, all 5 of 5 swine 
survived, while 1 out of 5 swine challenged at 21 days did not survive.  
 
 
 
 
 
 
 
 
 
 
 
 
 
7 Day 
Challenge 
14 Day 
Challenge 
21 Day 
Challenge 
Naive 
Challenge 
 111 
 4.3 Analysis of immune responses of swine infected with 
Geo∆9GL/∆UK  
Here we investigated the immune mechanisms present in swine surviving ASF 
challenge with a focus on circulating antibody, IFN-γ production in ASFV-stimulated 
PBMCs, as well as cytokines and chemokines in serum. 
The 5 swine that had been inoculated with 102 HAD50 of Geo∆9GL/∆UK and did 
not survive when challenged 28 days later did not have measurable antibody by ELISA 
and were either low or undetectable by IPA. When swine were inoculated with a 104 
HAD50 dose and challenged 28 days later, all swine survived the challenge with virulent 
Georgia 2007. Antibody titers were generally higher in these animals compared to those 
inoculated with a lower dose. Finally, when swine were inoculated with 106 HAD50, 14 
out of 15 swine survived the challenge and had the highest antibody levels at the time of 
challenge (28 days post-inoculation). The single non-survivor in the 106-vaccine group 
had the lowest antibody titers, around 10- to 100-fold less compared to the survivors 
receiving the same dose.  
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Figure 4.3 Anti-ASFV antibodies detected by ELISA and IPA, and IFN-γ-producing 
PBMCs 28 days post-inoculation with 102 HAD50 of Geo∆9GL/∆UK. Survival status 
of swine after challenge is indicated as “survived” (white open shapes), or “did 
not survive” (black filled shapes). Log10 values of anti-ASFV antibody titer 
detected by ELISA and IPA, and the number of circulating ASFV-specific IFN-γ-
producing PBMCs are represented for each individual pig. ELISA limit of 
detection:≤ Log10(1/10). IPA limit of detection:≤ Log10(1/200). 
 
Swine inoculated with 102 HAD50 had antibodies detectable in 4 out of 9 animals 
by ELISA and 6 out of 9 by IPA. Of the 6 swine presenting with antibody, 4 survived and 
2 did not. The IFN-γ production in PBMCs was lower in non-survivors when compared 
to survivors. 
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Figure 4.4 Anti-ASFV antibodies detected by ELISA and IPA, and IFN-γ-producing 
PBMCs 28 days post-inoculation with 104 HAD50 of Geo∆9GL/∆UK. Survival status 
of swine after challenge is indicated as “survived” (white open shapes), or “did 
not survive” (black filled shapes). Log10 values of anti-ASFV antibody titer 
detected by ELISA and IPA, and the number of circulating ASFV-specific IFN-γ-
producing PBMCs are represented for each individual pig. ELISA limit of 
detection:≤ Log10(1/10). IPA limit of detection:≤ Log10(1/200). 
 
Swine inoculated with 104 HAD50 had antibodies detectable in all 10 animals by 
ELISA and IPA. The IFN-γ production in PBMCs was elevated in all surviving swine. 
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Figure 4.5 Anti-ASFV antibodies detected by ELISA and IPA, and IFN-γ-producing 
PBMCs 28 days post-inoculation with 106 HAD50 of Geo∆9GL/∆UK. Survival status 
of swine after challenge is indicated as “survived” (white open shapes), or “did 
not survive” (black filled shapes). Log10 values of anti-ASFV antibody titer 
detected by ELISA and IPA, and the number of circulating ASFV-specific IFN-γ-
producing PBMCs are represented for each individual pig. ELISA limit of 
detection:≤ Log10(1/10). IPA limit of detection:≤ Log10(1/200). 
In swine inoculated with 106 HAD50, antibodies were detected in all 15 animals by 
ELISA and IPA, with the one non-survivor having the lowest antibody titer (Fig 4.5). The 
IFN-γ production in PBMCs was elevated in all surviving swine but highest in the single 
non-survivor. 
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Figure 4.6 Anti-ASFV antibodies detected by ELISA and IPA, and IFN-γ-producing 
PBMCs 7, 14 or 21 days post-inoculation with 104 HAD50 of Geo∆9GL/∆UK. 
Survival status of swine after challenge is indicated as “survived” (white open 
shapes), or “did not survive” (black filled shapes). Log10 values of anti-ASFV 
antibody titer detected by ELISA and IPA, and the number of circulating ASFV-
specific IFN-γ-producing PBMCs are represented for each individual pig. ELISA 
limit of detection:≤ Log10(1/10). IPA limit of detection:≤ Log10(1/200). 
ASFV antibodies were undetectable in all 5 animals challenged at 7 days post-
inoculation. Only one animal survived challenge, but antibody and IFN-γ did not differ 
between survivors and non-survivors in this challenge group. 
In the 14-day challenge group, all swine survived and had measurable levels of 
antibody by IPA and ELISA, along with the presence of IFN-γ production by the PBMCs. 
Swine in the 21-day group all had antibody detected by IPA and ELISA in 
addition to the IFN-γ production in stimulated PBMCs. One pig out of 5 did not survive 
the challenge in the 21-day challenge group and presented with the lowest count of 
PBMCs producing IFN-γ for that group. 
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Figure 4.7 Evaluation of systemic levels of different host cytokines at the time of 
challenge in swine inoculated with Geo∆9GL∆UK virus. Individual points 
represent data from each pig in the groups challenged at 7, 14, and 21 days post-
inoculation with Georgia 2007. All values are expressed as a concentration per 
mL of serum. Survival status of swine is indicated as “survived” (white open 
shapes), or “did not survive” (black filled shapes). 
Interferon-α (IFN-α) was 200-fold higher in surviving animals compared to non-
surviving animals, and transforming growth factor β (TGF-β) in surviving swine ranged 
from 1.5- to 2.5-fold higher compared to non-surviving swine in the 7- and 14-dpi 
groups. In general, the mean values did not vary greatly between protected and non-
protected swine. Other than IFN-α and TGF-β, no specific or unique patterns of cytokine 
levels in serum were observed in swine that did or did not survive. 
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Table 4.1 Survival status and fever responses in swine inoculated with 
Geo∆9GL/∆UK and subsequently challenged with Georgia 2007 
Group 
No. of 
Surviving 
Mean 
days until 
fever 
(±SD) 
Mean 
duration of 
fever in 
days (±SD) 
Maximum 
daily temp 
°C (±SD) 
Mean days 
until death 
(±SD) 
Control 0/5 3.6±0.6 5±0.5 40.8±0.7 7.6±0.1 
Geo ∆9GL/∆UK 
102 
2/5 3.3±0.7a 3.7±0.6a 41.2±0.9a 7.0±0.0a 
Geo ∆9GL/∆UK 
104 
5/5 - - 39.4±1.8 - 
Geo ∆9GL/∆UK 
106 
5/5 10.4±4.3b 4.0±2.8b 40.5±0.8b - 
Control 0/5 4.8±0.5 0.2±0.5 41.2±0.9 5.0±0.0 
Geo ∆9GL/∆UK 
102 
2/4 5.0±0.0c 1.5±0.7c 41.0±0.7c 5.5±0.7c 
Geo ∆9GL/∆UK 
104 
5/5 - - 39.7±0.9 - 
Geo ∆9GL/∆UK 
106 
5/5 10d 3d 40.4±0.0d - 
Control 0/5 3.8±0.5 1.2±0.5 40.9±0.3 5.0±0.0 
Geo ∆9GL/∆UK 
106 
4/5 11.0±2.6e 3.0±1.0e 40.2±0.6e 11.0e 
 
(a) Data is based on 3 out of 5 swine or (c) 2 out of 5 swine presenting severe clinical ASF in 
the first two experiments. The remaining 2 and 3 swine in the first and second experiments did 
not present ASF-related clinical signs. Their mean maximum daily rectal temperature was 
39.5°C with an SD of 0.9. 
(b) Data are based on 2 out of 5 swine that had transiently elevated rectal temperatures and 
mild clinical presentation. The remaining 3 swine did not present with any ASF-related clinical 
signs and their mean maximum daily rectal temperature was 39.2 °C with an SD of 0.2.  
(d) The data represents 1 out of 5 pigs that had a transient fever. The remaining four animals 
did not have any clinical signs of ASF, their mean rectal temperature was 39.5°C with an SD of 
0.5. 
(e) These data representing 2 out of 5 swine with transient rectal temperature elevations. One 
pig presented with severe clinical ASF and was euthanized 11 days post-challenge. The 
remaining 2 pigs did not show any ASFV-related clinical signs or fever. 
All swine were challenged at 28 days post-inoculation with 103 HAD50 Georgia 2007 
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Chapter 5 - Discussion 
 5.1 Importance of controlling foreign animal diseases 
Viral diseases of livestock are an important cause of food insecurity, economic 
losses and animal suffering across the globe. Producers in North America and Europe 
benefit from the fact that many of these diseases are absent from the hemisphere. 
Nevertheless, these ‘foreign’ animal diseases cause severe losses in other parts of the 
world, often depressing agricultural and human development in the poorest countries. 
Globalization and climate change increase the risk of re-introducing these diseases into 
free areas, especially diseases that can be spread by fomites or arthropod vectors. 
Their long-term control requires the application of effective measures in the most 
affected countries, which are the reservoirs of infection. In the meantime, countries with 
highly industrialized systems of densely stocked and fully susceptible livestock need 
contingency plans to deal with incursions. Reliance on slaughtering animals to halt 
epizootics is increasingly unacceptable on both economic and ethical grounds, making 
vaccination a critical element of both scenarios (Paton and Taylor, 2011). 
 5.2 Why vaccinating against ASFV is so important 
African swine fever (ASF) is a lethal hemorrhagic disease of swine caused by a 
double-stranded DNA virus. ASF virus (ASFV) is among the most important pathogens 
of domestic swine globally. There are 23 recognized genotypes of ASFV. This 
devastating disease can cause tremendous economic hardship due to the high mortality 
rate and the severe trade implications once ASFV is detected in a country. 
Since there is no vaccine available, our options for the containment and 
eradication of ASF are limited. In order to successfully eradicate ASF, an early detection 
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and notification system must be in place, teams of trained veterinarians must be able to 
recognize the disease in the field and send samples for rapid diagnosis at capable 
laboratories. This is critical in countries with high swine density populations, such as the 
U.S., in order to reduce economic losses. If the diagnosis of ASF is confirmed, the 
affected farms must be depopulated immediately with proper disposal of carcasses and 
a complete disinfection of the farm, vehicles, and other fomites.  
There are no effective vaccines against ASF, and their development is a high 
priority. Protective vaccination is feasible because complete protection can be achieved 
by infection with low-virulence isolates of ASFV. Convalescent swine develop strain-
specific immunity that can withstand challenge with antigenically related virulent strains. 
However, because of this strain specificity and a lack of heterologous protection, the 
goal must be to develop a vaccine capable of protection against multiple isolates. ASFV 
strains attenuated by cell culture passages, or targeted gene deletions have been used 
as experimental vaccines that elicit protective immune responses (Boinas et al., 2004; 
Hamdy and Dardiri, 1984; Leitao et al., 2001; Lewis et al., 2000; Mebus and Dardiri, 
1980; O'Donnell et al., 2015a; O'Donnell et al., 2015b). The use of naturally occurring 
attenuated ASF viruses has been explored as well, but unfortunately protection was 
variable with different challenge viruses (Souto et al., 2016).  
Pigs immunized with attenuated ASFVs containing genetically engineered 
deletions of specific virulence-associated genes are protected when challenged with 
homologous parental viruses. Specifically, individual deletions of UK (DP69R), 23-NL 
(DP71L), TK (A240L), or 9GL (B119L) genes from the genomes of virulent ASFVs 
resulted in significant attenuation of these isolates in swine (Lewis et al., 2000; Moore et 
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al., 1998; Zsak et al., 1998; Zsak et al., 1996). The deletion of these genes often 
reduces viral replication in primary macrophage culture and swine studies with these 
deletion mutants have shown that limiting the viral replication in macrophages 
dramatically reduces the virulence in domestic pigs. Reduced viral replication may avoid 
the induction of immunopathological processes and allow host defense mechanisms to 
clear the virus, but our understanding of how virulent and attenuated viruses interact 
with the host is limited.  
 5.3 Investigating the use of two attenuated mutants and determining 
an appropriate dose 
In this thesis we investigated those host defense mechanisms in swine protected 
against homologous challenge using four different ASFV strains including 
Pretoriuskop/96/4 (genotype I), its derivative Pret4∆9GL, Georgia 2007/1 (genotype II) 
and its derivative Geo∆9GL/∆UK (See Table 1 in Chapter 2). 
We first characterized the differences between Pret4 and Pret4∆9GL replication 
in vitro. A comparative growth curve at an MOI of 0.01 demonstrated Pret4∆9GL was 
delayed in replication compared to the parental Pret4 (Fig 3.1). These results are similar 
to those reported previously (Lewis et al., 2000; Neilan et al., 2004; O'Donnell et al., 
2015b; O'Donnell et al., 2016) where 9GL was deleted from Malawi Lil 20/1, Pret4, and 
Georgia 2007/1. In all these cases, growth curves of 9GL-deleted mutants and double 
mutants (∆9GL/∆MGF or ∆9GL/∆UK (see Appendix Fig A.8) demonstrated a delay in 
viral replication in swine macrophages when compared to the parental strains. ASFV 
infection results in the induction of mitochondrial stress-response proteins (Rojo et al., 
1998). With 9GL’s homology to ERV1, which is important for oxidative phosphorylation 
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and the maintenance of mitochondrial genomes in yeast, it is possible that p14, 
encoded by 9GL, may play a role in important mitochondrial functions in infected cells 
mediating that stress response (Lewis et al., 2000; Rojo et al., 1998). 
Interestingly, deleting the 9GL gene does not attenuate all isolates equally. We 
found that when 9GL was deleted from Georgia 2007, it was still highly virulent at high 
doses. Infection with 106 or 104 HAD50 was 100% fatal, but all swine survived when 
given 103 or 102 HAD50 (O'Donnell et al., 2015b). In contrast, when Malawi∆9GL was 
given at 106 HAD50 or 104 HAD50 and Pret4∆9GL at 104 HAD50, all swine survived and 
did not present with any clinical signs. 
Understanding the role of deleted ASFV genes is extremely complex because 
different ASF isolates behave differently with each deletion. Since ASFV Georgia 2007 
was not completely attenuated by deleting just 9GL, the double mutants 
Geo∆9GL/∆MGF (O'Donnell et al., 2016) and Geo∆9GL/∆UK (unpublished data) were 
generated. By itself, the deletion of 9GL or six genes of the MGF360/505 group created 
two attenuated ASFV strains that were able to induce a protective immune response 
against homologous challenge with virulent Georgia 2007. Unfortunately, the 
Geo∆9GL/∆MGF double mutant was over-attenuated. It did not cause any detectable 
viremia or antibody response in swine after administration of doses as high as 106 
HAD50 nor was there any protection against a subsequent virulent challenge (O'Donnell 
et al., 2016). 
Swine can be given Geo∆9GL/∆UK doses as high as 106 HAD50 to induce an 
antibody response by 28 days without any clinical disease. We found that the 104 HAD50 
dose was sufficient to stimulate a protective immune response when challenged at 28 
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days (100% survival), while a lower dose of 102 HAD50 only protected 40% of swine 
(4/10). This is significantly different compared to swine receiving 102 HAD50 of 
Malawi∆9GL, where 100% survived virulent challenge at 42 days, or Geo∆9GL, where 
100% of swine survived virulent challenge at 28 dpi after inoculation with 102 or 103 
HAD50 (Lewis et al., 2000; O'Donnell et al., 2015b). Swine administered 104 HAD50 
Pret4∆9GL and challenged 28 days later had an 80% survival rate (12/15) after 
repeating the experiment three times. Higher doses (106 HAD50) of Geo∆9GL/∆UK 
appeared to be less effective, as one animal did not survive a 28-day challenge, and 
4/15 of these animals had transient fever. 
 The variation in survival could be influenced by several factors. The initial 
virulence of the parental strain probably influences viral replication and the ability to 
stimulate a protective immune response. Also the genetics of swine can vary and 
influence how they respond to the attenuated virus. The Pret4∆9GL and Geo∆9GL/∆UK 
were repeated multiple times to gain a more representative sample of how domestic 
swine will respond to different doses of these attenuated viruses and at various times 
post-inoculation. 
 5.4 Comparative pathogenesis of Pret4 and Pret4∆9GL 
Our comparative pathogenesis experiment (see Fig. 3.2) demonstrated that 
during our 10-day observational period, Pret4∆9GL was attenuated in swine. Just four 
days after infection with either Pret4 we saw viremia peaks above 107/ml, whereas 
Pret4∆9GL was detected at a 1000-fold lower level (see Fig. 3.3). No nasal shedding of 
the Pret4∆9GL virus was detected, while from 4 to 10 days post-infection Pret4 was 
detected in all nasal swab samples (see Fig. 3.3). These results are similar to our recent 
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publication with Geo∆9GL, where swine inoculated with 102 or 103 did not present with 
any nasal shedding of the attenuated virus (O'Donnell et al., 2015b), although shedding 
was apparent with the parental Georgia 2007 strain (Guinat et al., 2014).  
None of our swine inoculated with Pret4∆9GL presented with any clinical signs of 
disease (changes in mentation, neurologic signs, or melena) (see Fig. 3.4). This was 
shown previously by (Neilan et al., 2004) for a 42-day period. Swine infected with Pret4, 
on the other hand, developed fever and clinical signs including diarrhea, lack of 
appetite, and a listless attitude as early as 4 dpi. 
As a part of our study to investigate differences in virus distribution at early time 
points of infection with Pret4 or Pret4∆9GL, we performed necropsies on swine every 
other day for 10 days. What we found was that at 2, 4, 6, and 10 days post-infection we 
were able to detect low level of virus in spleen macerate in swine infected with either 
virus (Fig 3.5). Other than spleen, lung or liver we did not detect the Pret∆9GL virus in 
the other 7 organs collected. The Pret∆9GL virus did not replicate well in swine during 
the 10-day observational period, unlike its virulent parental strain Pret4, which was 
isolated from all organs beginning at 4 dpi. Although we detected virus in spleen 
macerate, we were unable to detect ASFV antigen in the spleen by IHC. The spleen is a 
very blood-rich organ and it is possible that our virus isolation from the spleen could be 
a direct result of viremia, and not necessarily local replication of virus. Individual animal 
data (Appendix A Fig 6.2-5) illustrates the heterogeneity in Pret4∆9GL replication 
between animals, which makes it difficult to predict a certain level of replication 
necessary for a protective response. As seen with OUR T88/4, sporadic viremia and 
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less efficient transmission was also characteristic of non-pathogenic non-hemadsorbing 
isolates (Boinas et al., 2004).  
Having a virus that is attenuated adequately to not cause clinical disease, but still 
able to replicate sufficiently to induce protection against challenge with a homologous 
virulent strain, is an important step toward understanding how the host responds to 
ASFV.  
 5.5 Onset of protective immunity of Pret∆9GL and Geo∆9GL/∆UK 
Protective immune responses induced by attenuated viruses have been 
investigated previously. It has been suggested that passive transfer of antibodies from 
immunized swine to naïve swine could confer protection against virulent challenge 
(Onisk et al., 1994). Other reports suggest that antibodies cannot completely neutralize 
ASFV, and the presence of neutralizing antibodies has been controversial (Gomez-
Puertas and Escribano, 1997; Neilan et al., 2004; Zsak et al., 1993). 
To understand the basis of protection when swine are challenged at different 
time points (7, 10, 14, 21, 28 days post-inoculation), we sought to find correlates of 
different virological and immunological parameters and the survival status after a 21-day 
observational period following homologous challenge. Our focus was to quantify 
Pret∆9GL viremia, circulating antibodies, ASFV-stimulated PBMCs producing IFN-γ, 
and several cytokines and chemokines present in the serum at the time of challenge. 
This model allowed us to analyze the immunological status of swine that did or 
did not survive the challenge at different times post-vaccination. By challenging swine 
early (7, 10, 14 dpi) and late (21, 28 dpi) we could monitor the presence of different 
immune parameters that may change during the maturation of the host response 
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between 0 and 28 days after inoculation with Pret4∆9GL. We were astounded to find 
40-73% of Pret4∆9GL-inoculated swine survived challenge at 7, 10, 14 dpi. This is the 
first report of swine surviving when challenged earlier than 3 weeks after 
inoculation. The existence of protection so early indicates that partially effective early 
host immune mechanisms are at play. It is not clear what host immune mechanisms are 
providing such early protection. However, none of the host parameters analyzed in the 
Pret4∆9GL animals correlated with an animal surviving challenge. When we looked at 
the early challenges of swine inoculated with Geo∆9GL/∆UK, we found 20-100% of 
swine surviving challenge with virulent Georgia at 7 and 14 dpi.  
Viremia in Pret4∆9GL swine surviving the challenge was present with a broad 
range of titers (103 to 108 log10 HAD50/mL peaking at day 7-10 post-challenge) in all 
groups at almost all the time points tested during the observational period of 21 days 
post-challenge. It appears that the clinical presentation of ASF, as well as kinetics of 
virus replication systemically in swine, whether surviving virulent challenge or not, are 
very similar regardless the time of challenge. These results were unanticipated as we 
might expect that immune mechanisms develop at different times post-infection with 
Pret4∆9GL would be quantitatively or qualitatively different. Consequently, we expected 
that the level or type of immune response protecting swine from a virulent challenge 
would be different. With this expectation, we though this difference may be shown in the 
outcome following challenge with swine protected or not protected from the Pret4 
challenge. Conversely, the analysis of viremia in Geo∆9GL/∆UK-infected animals in the 
28-day challenge groups revealed that, regardless of the dose received, swine had 
different viremia kinetics after challenge (O’Donnell et al 2016, submitted). These swine 
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had a small transient peak of viremia, then decreased until viremia titers were low (103 
HAD50/ml) or undetectable in 17 of the 25 survivors by 21 days post-challenge 
(O’Donnell et al 2016, submitted). 
The presence of anti-ASFV antibodies appears to be associated with protection. 
Although absent at 7 and 10 dpi, they were detected in swine inoculated with 
Geo∆9GL/∆UK at 14, 21, and 28 dpi and in swine inoculated with Pret4∆9GL at 21 and 
28 dpi. Among swine inoculated with 102 HAD50 Geo∆9GL/∆UK and challenged at 28 
dpi, non-survivors generally did not have detectable anti-ASFV antibodies, whereas the 
four survivors did. With swine inoculated with Pret4∆9GL and challenged at 21 or 28 
days, all surviving animals (80%) had detectable antibodies. In the Pret4∆9GL 14-day 
challenge where 73% survived, one of the 3 non-survivors had antibody levels higher 
than any survivor. These variations between individuals are difficult to explain. We 
suspect that as more time passes between inoculation with an attenuated strain and the 
virulent challenge, the immune response matures to respond more specifically and 
possibly quicker. Looking at the big picture, swine challenged later with Pret4∆9GL (21 
and 28 days) and Geo∆9GL/UK (14,21, and 28) demonstrated an association between 
the presence of anti-ASFV antibodies and protection from virulent challenge. 
Previously it was reported that CD8+ T cells were essential for a protective 
immune response when induced by OUR T88/3 and challenged with OUR T88/1 (Oura 
et al., 2005). Further evidence suggesting the importance of lymphocytes in a protective 
immune response was reported in experiments demonstrating cross protection induced 
by the OUR T88/3 isolate against challenge with virulent isolates from different 
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genotypes, where protection was correlated with the capacity to stimulate IFN-γ in 
PBMCs from immunized swine (King et al., 2011).  
Based on previous reports correlating the presence of IFN-γ in PBMCs of 
vaccinated animals with protection (Argilaguet et al., 2012; King et al., 2011), we 
expected to find some correlation between survival status after challenge and the 
number of IFN-γ-producing PBMCs. However, in both models (Pret4∆9GL and 
Geo∆9GL/∆UK), IFN-γ production in PBMCs alone was not associated with protection. 
In many of the Pret4∆9GL swine the IFN-γ ELISPOT was performed weekly to further 
investigate any patterns associated with protection. In many non-survivors, the number 
of IFN-γ-producing PBMCs declined as the health of the animal deteriorated (see 
appendix A, swine numbered in red). In many of the surviving swine, the challenge virus 
acted as a booster in the IFN-γ response in PBMCs, as the number of IFN-γ-producing 
cells increased in the weeks after challenge (see appendix A, swine numbered in 
green). 
 5.6 Open questions about the role of cytokines 
Reports suggest elevations of TNF-α, and IL-1β play a major role in ASF 
pathogenesis due to their proinflammatory, proapoptotoic, and procoagulant action 
(Gomez-Villamandos et al., 2013; Zakaryan et al., 2015). Cytokines and chemokines 
measured at 7, 10, and 14 days post-inoculation in swine sera with Pret4∆9GL did not 
yield any particle pattern related to survival. Among the groups tested there were 
variations in cytokine and chemokine levels in all groups regardless of each group’s 
clinical outcome. More recently, Reis et al. (2016) also looked at IL-1β, IL-4, TNFα, IFN-
γ, and IL-10 in serum, and did not find significant differences in cytokine levels in swine 
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infected with ASFV Benin∆MGF or OUR T88/3, with the exception of elevated IFN-γ at 
5 and 7 dpi in swine immunized with Benin∆MGF (Reis et al., 2016).  
In swine inoculated with Geo∆9GL/∆UK, IFN-α and TGF-β levels were elevated 
in the only animal surviving challenge at 7 days post-inoculation when compared to 
other animals that did not survive. Two groups have demonstrated a reduction of ASFV 
replication in monocytes/macrophages by IFN-α and porcine IFN-γ (Esparza et al., 
1988) as well as by human IFN-α and IFN-γ in Vero cells (Paez et al., 1990). However, 
Golding et al. (2016) found that virulent ASFV continues to replicate in the presence of 
circulating IFN-α. Afonso and Golding reported that MFG360/530 genes affect the IFN-α 
production in macrophage cultures when comparing Pret4∆35 and Pret4 (Afonso et al., 
2004; Golding et al., 2016). Attenuated viruses lacking MGF genes (Pret4∆35 and 
OURT88/1) are unable to block the host IFN-α response (Golding et al., 2016). 
Attenuated strains of ASFV are currently the most reasonable approach to 
develop an ASF vaccine. Several attenuated strains obtained by genetic manipulation 
have demonstrated the ability to induce protective immune responses against virulent 
strains of ASF. In this thesis we explore a number of immunologic and viral parameters 
in association with protection against challenge. We have developed an in-house 
immunoperoxidase assay and an indirect ELISA assay to detect ASFV-specific swine 
IgG in sera. Both assays were able to detect an IgG response against ASFV as early as 
7 or 11 dpi. Results from the ELISA and IPA demonstrate that the presence of 
antibodies at later challenge time points (21 and 28 dpi, as well as 14 dpi for 
Geo∆9GL/∆UK) is associated with survival in a majority of animals. 
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Although IFN-γ did not correlate with a protective immune status, we found that 
IFN-γ increased continuously for the 3 weeks following challenge. These results, 
encompassing data from over 114 immunized swine, underscore the complexity of the 
system under study where it is very plausible that protection against disease or infection 
relies heavily on the concurrence and or interaction of different host immune 
mechanisms. 
 5.7 Potential problems 
Effective vaccines against ASF must prevent viral replication to minimize the 
effects of the virulent virus causing damage to the host (Wardley and Wilkinson, 1985). 
It is well known that the vaccine strain used in the 1960’s in Portugal killed up to 
7% of vaccinated swine and at times chronic carriers of ASFV ensued (Boinas et al., 
2004; Nunes Petisca, 1965). A substantial portion of these animals had reactions 
ranging from skin ulcers, pneumonia and abortion to death (Manso Ribeiro et al., 1963). 
The vaccine was the Lisbon 60 isolate passaged up to 150 times in swine PBMCs 
(Manso Ribeiro et al., 1963). 
The naturally attenuated OURT T88/3 isolate has been shown to induce a 
protective immune response against virulent homologous challenge (Boinas et al., 
2004; King et al., 2011; Oura et al., 2005). Adverse reactions including fever and joint 
swelling have been observed in some pigs post-inoculation. A transient fever was 
described in 5 out of 12 swine immunized with OUR T88/3 in one study (King et al., 
2011). 
Research investigating the potential existence of an ASFV carrier state, where 
swine are shedding ASFV without presenting clinical signs is necessary. Chronic forms 
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of ASF have been described in swine experimentally infected with attenuated strains 
from previous outbreaks in Europe (de Carvalho Ferreira et al., 2012; Gallardo et al., 
2015; Wilkinson et al., 1981). If any attenuated virus is to be licensed as a vaccine, 
extensive studies will be needed to look at the safety of the vaccine and the absence of 
the development of chronic ASF. Swine inoculated with the vaccine virus should be 
necropsied at early and late times to observe the tropism of the virus and potential 
debilitating lesions associated with that virus.  
 5.8 Future experiments and outlook 
Immunological and pathological aspects of ASFV remain to be elucidated. This 
thesis sought to further our knowledge of host factors that influence protection against 
death against ASFV. Based on the results presented here, similar experiments in the 
future should put an emphasis on the collection of more clinical pathology data. 
Flow cytometry to characterize changes in defined immune cell types including 
cytotoxic T cells (CD3+CD8+), γδ T cells (CD3+γδTCR+), helper T cells (CD3+CD4+), 
or NK cells (CD3-CD4-CD6-CD8α+) (Gerner et al., 2009) may help to delineate 
changes in the immune response to the attenuated vaccine virus and the challenge 
virus. The IFN-γ responses measured by ELISPOT could be further characterized by a 
flow cytometry assay with gating on different T cell subsets, macrophages 
(CD163+/CD172+) and NK cells in combination with intracellular staining for IFN-γ. 
Incorporating complete blood counts (CBCs) and blood chemistry could help to 
predict the survival outcome of the animals. With a CBC we would have general counts 
of monocytes, lymphocytes, neutrophils, eosinophils, basophils and erythrocytes. As 
reported previously, (Zakaryan et al., 2015), swine succumbing to an ASFV challenge 
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will have lymphopenia and varying numbers of monoblasts (immature monocytes) and 
lymphoblasts. With this information we may be able to better gauge an animal’s health 
status and aid our veterinarians and technicians in deciding to euthanize experimental 
animals to avoid unnecessary suffering. As we get closer to a more promising vaccine 
such parameters will be critical to monitoring swine health after vaccination and 
challenge. 
Improving our methods for virus isolation and growth is another critical need 
related to the development of potential vaccines. Currently we rely on primary 
macrophage cultures to grow our attenuated viruses, because Vero-adapted ASFV 
virus did not stimulate protective immune responses in swine. We need a cell line that 
allows us to scale up the quantities of virus we grow, while giving us excellent quality 
control for a clean and reliable cell line. 
It would be important to test our mutant viruses after a booster injection with the 
same attenuated virus around 2-3 weeks to see how that changes the effectiveness of 
the immune response. If better success is found with booster vaccination schedules, an 
attempt to booster animals with two different attenuated strains and challenging animals 
with either parental virus could provide interesting results. 
Better descriptions of pathogenesis and possible mechanisms for persistent or 
chronic ASF infections should be investigated. Understanding this development is 
relevant for disease control as well as for vaccine design and efficacy. Further studies 
are necessary to investigate chronic and persistent infections, because it is little 
understood how they impact their host and the epidemiology of ASF in various regions. 
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The studies here investigate protection against a virulent challenge with a 21-day 
observational period. In future experiments, swine should be monitored longer for any 
significant health changes as swine suffering from chronic forms of ASF do not have 
specific lesions and may linger for months. In our experiments, we have live attenuated 
and virulent strains replicating in our swine after challenge, therefore further 
investigation of how this relates to an animal’s long-term health status should be 
pursued. 
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Appendix A - Supplemental Figures 
The figures below show individual animal data from the Pretoria onset of 
protection experiments. All swine that did not survive challenge are numbered in red. 
Swine that did survive challenge are numbered in green. 
 
Figure A.5.1 Legend for Individual graphs 
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Figure A.5.2 Individual animals in control group. Left axis: rectal temperature 
(black) (°C). Right axis: Log10 of viremia titer (orange), anti-ASFV antibody by IPA 
(blue), anti-ASFV antibody by ELISA (green), and IFN-γ spots per 5X105 PMBCs 
(red bars) of naïve swine challenged on day 0. 
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Figure A.5.3 Individual animals in 7-day group. Left axis: rectal temperature 
(black) (°C). Right axis: Log10 of viremia titer (orange), anti-ASFV antibody by IPA 
(blue), anti-ASFV antibody by ELISA (green), and IFN-γ spots per 5X105 PMBCs 
(red bars) of naïve swine challenged 7 days post-inoculation (=day 0). 
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Figure A.5.4 Individual animals in 10-day group. Left axis: rectal temperature 
(black) (°C). Right axis: Log10 of viremia titer (orange), anti-ASFV antibody by IPA 
(blue), anti-ASFV antibody by ELISA (green), and IFN-γ spots per 5X105 PMBCs 
(red bars) of naïve swine challenged 10 days post-inoculation (=day 0). 
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Figure A.5.5 Individual animals in 14-day group. Left axis: rectal temperature 
(black) (°C). Right axis: Log10 of viremia titer (orange), anti-ASFV antibody by IPA 
(blue), anti-ASFV antibody by ELISA (green), and IFN-γ spots per 5X105 PMBCs 
(red bars) of naïve swine challenged 14 days post-inoculation (=day 0). 
*Note that IFN-γ was not tested in swine 3927 through 39731. 
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Figure A.5.6 Individual animals in 21-day group. Left axis: rectal temperature 
(black) (°C). Right axis: Log10 of viremia titer (orange), anti-ASFV antibody by IPA 
(blue), anti-ASFV antibody by ELISA (green), and IFN-γ spots per 5X105 PMBCs 
(red bars) of naïve swine challenged 21 days post-inoculation (=day 0). 
 
*Note that the two non-survivors and three survivors were not tested for IFN-γ by 
ELISPOT. The 14-dpc samples were not tested in this group. 
 
 
 
 
 
 
 157 
 
Figure A.5.7 Individual animals in 28-day group. Left axis: rectal temperature 
(black) (°C). Right axis: Log10 of viremia titer (orange), anti-ASFV antibody by IPA 
(blue), anti-ASFV antibody by ELISA (green), and IFN-γ spots per 5X105 PMBCs 
(red bars) of naïve swine challenged 28 days post-inoculation (=day 0). 
*Note, IFN-γ was only tested at -7, 0, 7 dpc in swine 45350 through 45356.  
IFN-γ was tested once a week throughout the entire study for swine 44313, 44327, 
44328, 44329, 44330.  
IFN-γ was not tested in the first experiment in swine 38739-38742. 
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Figure A.5.5.8 In vitro growth characteristics of Geo∆9GL, Geo∆9GL/∆UK, and 
parental strain ASFV-Georgia 2007. Swine macrophage cultures were infected 
(MOI 0.01), with each virus and titrated at the 2, 24,48,72, and 96 hours post-
infection. Data represent means and SD from three independent experiments. 
Limit of virus detection ≥ 1.8 Log10 HAD50/mL.  
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Appendix B - Reagents 
Table 5.1 List of supplies used throughout this thesis 
Reagents/Supplies Manufacturer Catalogue Number 
DPBS 1X Gibco/Invitrogen 14190-144 
Antibiotic/Antimycotic Gibco/Invitrogen 15240-062 
EDTA 0.5 M Corning Cellgro 46-034-CI 
Fetal Bovine Serum (Gamma 
Irradiated) 
HyClone SH30071-03 
Ficoll-Plaque Plus GE Healthcare 17-1440-02 
Filter 0.45 um for 500 ml Corning 430770 
Filter 0.22 um for 500 ml Corning 430769 
Gentamicin Gibco/Invitrogen 15750-060 
HEPES Gibco/Invitrogen 15630-0808 
Primaria 6-Well Falcon Becton Dickinson 353846 
Primaria 96-Well Falcon Becton Dickinson 353872 
Primaria T75 Falcon Becton Dickinson 353810 
Roller Bottle 2 L Corning 430849 
RPMI Media 1640 Gibco/Invitrogen 21870-076 
Trypsin EDTA 0.05% Gibco/Invitrogen 25300-054 
Vectastain (ABC kit) Peroxidase 
Mouse IgG 
Vector PK-4002 
 
Vectastain Peroxidase Standard Vector PK-4000 
Vector VIP Peroxidase Substrate 
Kit 
Vector SK-4600 
 
1kb DNA Ladder Promega G571A 
Biotyinylated Anti-Swine IgG 
(H+L) 
Vector BA-9020 
Blue/Orange Loading Dye Promega G190A 
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